HPV-16 t cell receptor uses and compositions thereof

Abstract

The present disclosure provides T cell receptors (TCRs) against peptide-MHC complexes, isolated nucleic acid molecules encoding TCRs against peptide-MHC complexes, T cells expressing TCRs against peptide-MHC complexes, and pharmaceutical compositions for use in the treatment of HPV associated disease or cancer.

Description

WSGR Docket No. 50401-806.601HPV-16 T CELL RECEPTOR USES AND COMPOSITIONS THEREOFCROSS-REFERENCE

[0001] This application claims the benefit of U.S. Provisional Application No. 63 / 692,923, filed on September 10, 2024, which is incorporated herein by reference in its entirety.BACKGROUND

[0002] T cell receptors (TCRs) are members of the immunoglobulin superfamily and usually consist of two subunits, namely the a- and P-subunits. These possess one N-terminal immunoglobulin (Ig)-variable (V) domain, one Ig-constant (C) domain, a transmembrane / cell membrane-spanning region, and a short cytoplasmic tail at the C-terminal end. The variable domains of both the TCR a-chain and P-chain have three hypervariable or complementarity determining regions (CDRs), whereas the variable region of the P-chain has an additional area of hypervariability (HV4) that does not normally contact antigen and therefore is not considered a CDR.

[0003] CDR3 is the principal CDR responsible for recognizing processed antigen, although CDR1 of the alpha chain has also been shown to interact with the N-terminal part of the antigenic peptide, whereas CDR1 of the P-chain interacts with the C-terminal part of the peptide. CDR2 is thought to recognize the MHC. The constant domain of the TCR domain consists of short connecting sequences in which a cysteine residue forms disulfide bonds, which forms a link between the two chains. The affinity of TCR’ s for a specific antigen makes them valuable for several therapeutic approaches. For example, cancer patients, such as melanoma patients, can be effectively treated by using adoptive immunotherapy as TCRs are exquisitely sensitive for their antigen and can direct immune responses at tumor cells expressing their cognate antigen. Accordingly, there is a need for TCRs against peptide-MHC complexes for development of new and effective therapeutics.SUMMARY

[0004] Provided herein is a recombinant nucleic acid encoding a T cell receptor (TCR) comprising a TCR beta chain and a TCR alpha chain, wherein the TCR binds to an E7 epitope from human papillomavirus (HPV) in complex with a human MHC encoded by an HLA- A*02:01 allele with an ECso of more than 0.2 nM, and wherein the E7 epitope comprises a sequence of SEQ ID NO: 286.WSGR Docket No. 50401-806.601

[0005] In some embodiments, the EC50 is more than 0.2 nM and less than 100 nM. In some embodiments, the EC50 is more than 0.2 nM and less than 50 nM. In some embodiments, the EC50 is more than 0.5 nM and less than 15 nM.

[0006] In some embodiments, the TCR does not lead to resistance by a subject being administered with a therapeutic agent comprising the TCR.

[0007] In some embodiments, the TCR is a soluble TCR. In some embodiments, the TCR does not comprise a TCR alpha constant domain and / or a TCR beta constant domain. In some embodiments, the TCR is a membrane-bound TCR. In some embodiments, the TCR further comprises a TCR alpha constant domain and / or a TCR beta constant domain. In some embodiments, the TCR alpha constant domain comprises a sequence of SEQ ID NOs: 287or 288. In some embodiments, the TCR beta constant domain comprises a sequence of SEQ ID NOs: 289-292.

[0008] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 170. In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 5. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 6. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 171. In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 166; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 167; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 168. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 169.

[0009] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 278. In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 5. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 6. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%WSGR Docket No. 50401-806.601 sequence identity to an amino acid sequence set forth in SEQ ID NO: 279. In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 17; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 18; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 276. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 277.

[0010] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 7. In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 5. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 6. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 8. In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 1; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 2; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 3. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 4.

[0011] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 15. In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 16.In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 9; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 10; and the CDR3 has an amino acid sequence set forth inSEQ ID NO: 11. In some embodiments, the TCR alpha chain comprises a variable region havingWSGR Docket No. 50401-806.601 at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 12.

[0012] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 15. In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 16.In some embodiments, 36-39, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 17 ; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 18; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 19. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 20.

[0013] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 28. In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 26. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 27. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 29.In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 21; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 22; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 24. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 25.WSGR Docket No. 50401-806.601

[0014] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 32. In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 33. In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 9; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 10; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 30. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 31.

[0015] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 32. In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 33. In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 9; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 10; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 34. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 35.

[0016] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 36. In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2),WSGR Docket No. 50401-806.601 wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 37. In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 9; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 10; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 34. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 35.

[0017] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 44. In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 42. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 43. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 45. In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 38; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 39; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 40. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 41.

[0018] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 50. In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 51.WSGR Docket No. 50401-806.601In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 46; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 47; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 48. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 49.

[0019] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 56. In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 57. In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 52; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 53; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 54. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 55.

[0020] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 58. In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 59. In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 52; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 53; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 54. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, atWSGR Docket No. 50401-806.601 least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 55.

[0021] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 58. In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 59. In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 9; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 10; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 60. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 61.

[0022] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 66. In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 67.In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 62; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 63; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 64. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 65.

[0023] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 74. In some embodiments, the TCR beta chain comprises a complementarity determining region 1WSGR Docket No. 50401-806.601(CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 72. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 73. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 75. In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 68; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 69; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 70. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 71.

[0024] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 82. In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 80. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 81. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 83. In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 76; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 77; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 78. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 79.

[0025] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 88. In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%WSGR Docket No. 50401-806.601 sequence identity to an amino acid sequence set forth in SEQ ID NO: 89. In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 84; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 85; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 86. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 87.

[0026] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 94. In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 92. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 93. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 95. In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 52; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 53; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 90. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 91.

[0027] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 98. In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 26. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 27. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 99. In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 17; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 18; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 96. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, atWSGR Docket No. 50401-806.601 least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 97.

[0028] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 106. In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 104. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 105. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 107. In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 100; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 101; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 102. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 103.

[0029] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 112. In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 113. In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 108; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 109; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 110. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 111.

[0030] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 118. In some embodiments, the TCR beta chain comprises a complementarity determining region 1WSGR Docket No. 50401-806.601(CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 5. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 6. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 119. In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 114; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 115; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 116. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 117.

[0031] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 124. In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 26. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 27. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 125. In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 120; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 121; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 122. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 123.

[0032] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 130. In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 130. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%WSGR Docket No. 50401-806.601 sequence identity to an amino acid sequence set forth in SEQ ID NO: 131. In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 126; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 127; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 128. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 129.

[0033] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 134. In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 135. In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 84; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 85; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 132. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 133.

[0034] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 138. In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 139. In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 52; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 53; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 136. In some embodiments, the TCR alpha chain comprises a variable region having at leastWSGR Docket No. 50401-806.60180%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 137.

[0035] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 142. In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 143. In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 9; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 10; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 140. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 141.

[0036] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 146. In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 26. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 27. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 147. In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 17; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 18; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 144. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 145.

[0037] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 150. In some embodiments, the TCR beta chain comprises a complementarity determining region 1WSGR Docket No. 50401-806.601(CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 151. In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 52; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 53; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 148. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 149.

[0038] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 154. In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14.In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 144. In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 52; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 53; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 152. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 153.

[0039] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 158. In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%WSGR Docket No. 50401-806.601 sequence identity to an amino acid sequence set forth in SEQ ID NO: 159. In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 9; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 10; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 156. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 157.

[0040] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 164. In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 72. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 73. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 165. In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 160; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 161; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 162. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 163.

[0041] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 174. In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 5. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 6. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 175. In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 84; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 85; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 172. In some embodiments, the TCR alpha chain comprises a variable region having at leastWSGR Docket No. 50401-806.60180%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 173.

[0042] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 180. In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 181. In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 176; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 177; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 178. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 179.

[0043] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 184. In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 72. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 73. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 185. In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 176; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 177; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 182. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 183.

[0044] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 190. In some embodiments, the TCR beta chain comprises a complementarity determining region 1WSGR Docket No. 50401-806.601(CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 191. In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 186; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 187; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 188. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 189.

[0045] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 196. In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 194. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 195. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 197.In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 17; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 18; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 192. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 193.

[0046] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 164. In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 72. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 73. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at leastWSGR Docket No. 50401-806.60185%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 165. In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 160; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 161; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 162. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 163.

[0047] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 202. In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 203. In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 198; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 199; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 200. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 201.

[0048] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 206. In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 107. In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 84; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 85; and the CDR3 has an amino acid sequence set forth in SEQ ID NO:WSGR Docket No. 50401-806.601204. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 205.

[0049] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 36. In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 37. In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 9; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 10; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 208. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 209.

[0050] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 216. In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 214. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 215. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 217. In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 210; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 211; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 212. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 213.

[0051] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 222.WSGR Docket No. 50401-806.601In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 223. In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 218; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 219; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 220. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 221.

[0052] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 226. In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 72. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 73. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 227. In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 186; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 187; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 224. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 225.

[0053] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 230. In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 5. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 6. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%,WSGR Docket No. 50401-806.601 at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 231. In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 17; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 18; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 228. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 229.

[0054] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 234. In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 5. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 6. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 235. In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 218; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 219; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 232. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 233.

[0055] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 238. In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 5. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 6. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 239. In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 84; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 85; and the CDR3 has an amino acid sequence set forth in SEQ ID NO:WSGR Docket No. 50401-806.601236. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 237.

[0056] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 240. In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 5. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 6. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 241. In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 166; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 167; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 168. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 169.

[0057] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 244. In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 26. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 27. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 245. In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 38; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 39; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 242. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 243.

[0058] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 248.WSGR Docket No. 50401-806.601In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 249. In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 9; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 10; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 246. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 247.

[0059] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 252. In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 253. In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 176; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 177; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 250. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 251.

[0060] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 256. In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 72. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 73. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%,WSGR Docket No. 50401-806.601 at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 257. In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 68; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 69; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 254. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 255.

[0061] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 262. In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 26. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 27. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 263. In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 258; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 259; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 260. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 261.

[0062] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 266. In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 267. In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 52; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 53; and the CDR3 has an amino acid sequence set forth in SEQ ID NO:WSGR Docket No. 50401-806.601264. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 265.

[0063] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 274. In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 272. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 273. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 275. In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 268; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 269; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 270. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 271.

[0064] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 284. In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 282. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 283. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 285. In some embodiments, the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 46; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 47; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 280. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 281.

[0065] Provided herein is a T cell comprising the recombinant nucleic acid of any one of the embodiments herein. In some embodiments, the T cell is a CD4+ T cell or a CD8+ T cell.WSGR Docket No. 50401-806.601

[0066] Provided herein is a soluble TCR encoded by the recombinant nucleic acid of any one of the embodiments herein.

[0067] Provided herein is a pharmaceutical composition comprising: (a) (i) the recombinant nucleic acid of any one of the embodiments herein; and (b) a pharmaceutically acceptable excipient or diluent.

[0068] Provided herein is a use of the pharmaceutical composition of any one of the embodiments herein, the cell of any one of the embodiments herein, or the soluble TCR of any one of the embodiments herein, for treating an HPV associated cancer.

[0069] Provided herein is a method of treating an HPV associated cancer in a subject in need thereof, comprising administering to the subject the pharmaceutical composition of any one of the embodiments herein. In some embodiments, the HPV associated cancer is caused by HPV- 16. In some embodiments, the HPV associated cancer is selected from the group consisting of head and neck squamous cell carcinoma, oropharyngeal cancer, cervical carcinoma, anogenital carcinoma, and penile carcinoma. In some embodiments, the HPV associated cancer is refractory or relapsed.INCORPORATION BY REFERENCE

[0070] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.BRIEF DESCRIPTION OF THE DRAWINGS

[0071] The novel features of the disclosure are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present disclosure will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the disclosure are utilized, and the accompanying drawings of which:

[0072] FIGs. 1A-1C depict a clinical study design for determining the effect of an HPV vaccine. FIG. 1A depicts the timeline of when tumor tissue, cytokines and antibody response were analyzed for all patients during the clinical study. FIG. IB depicts the timeline of when the immune response and TCR profiling were analyzed for all patients during the clinical study. FIG. 1C depicts the timeline of when the TCR profiling and immunohistochemistry of tissue samples were analyzed for patients in Arm IB only.WSGR Docket No. 50401-806.601

[0073] FIG. 2A-2B depict the immune response summary of the patients treated with different dosage of the HPV vaccine. FIG. 2A depicts the immune response summary of the patients in Arm 1 A. FIG. 2B depicts the immune response summary of the patients in Arm IB.

[0074] FIG. 3 depicts the analysis of T cell receptor beta chain (TRB) repertories, and the clonotype enrichment of TRB and T cell receptor alpha chain (TRA) of the patients treated with the HPV vaccine.

[0075] FIG. 4 depicts the TRB cumulative frequency of functional TCRs of a representative patient sample across different timepoints.

[0076] FIG. 5 illustrates an experimental schema for performing a luciferase Jurkat-reporter assay to validate TCRs.

[0077] FIGs. 6A-6H depict the results of the luciferase Jurkat-reporter assay performed with target cells expressing different HLA alleles in complex with E6 or E7 peptides. FIG. 6A depicts luciferase Jurkat-reporter assay performed with target cells expressing A*02:01. FIG. 6B depicts luciferase Jurkat-reporter assay performed with target cells expressing A*32:01. FIG. 6C depicts luciferase Jurkat-reporter assay performed with target cells expressing B* 14:01. FIG. 6D depicts luciferase Jurkat-reporter assay performed with target cells expressing B*51:01. FIG. 6E depicts luciferase Jurkat-reporter assay performed with target cells expressing C*07:02. FIG. 6F depicts luciferase Jurkat-reporter assay performed with target cells expressing C*08:02. FIG. 6G depicts luciferase Jurkat-reporter assay performed with target cells expressing DRB 1*13:01. FIG. 6H depicts luciferase Jurkat-reporter assay performed with target cells expressing DRB1*14:54.

[0078] FIG. 7 depicts reactivity of TCRs at varying peptide concentration, as measured by luciferase Jurkat-reporter assay.

[0079] FIG. 8 depicts reactivity of the identified TCR at varying peptide concentration, as measured by luciferase Jurkat-reporter assay, and the avidity of the different TCRs.

[0080] FIG. 9 depicts the percentage of CD3+ T cells expressing the different TCRs.

[0081] FIG. 10 depicts the percent multimer positive of CD8 or CD4 T cells with expression of different TCRs.

[0082] FIG. 11 depicts cytotoxicity of cells expressing different TCRs upon co-culturing with Caski cells.

[0083] FIG. 12 depicts functional avidity and affinity of different HPV E7 TCRs.

[0084] FIGs. 13A-13B depict result of cytotoxicity assay. FIG. 13A depicts cytotoxicity of cells expressing different TCRs upon co-culturing with Caski cells. FIG. 13B depicts cytotoxicity of cells expressing different TCRs upon co-culturing with SCC152 or Caski cells.WSGR Docket No. 50401-806.601DETAILED DESCRIPTIONDefinitions

[0085] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present disclosure, the preferred methods and materials are now described. The details of one or more particular embodiments are set forth in the description below.

[0086] The term “about” or “approximately” means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, e.g., the limitations of the measurement system. For example, “about” can mean within 1 or more than 1 standard deviation, per the practice in the art. Alternatively, “about” can mean a range of up to 20%, up to 10%, up to 5%, or up to 1% of a given value. Alternatively, particularly with respect to biological systems or processes, the term can mean within an order of magnitude, preferably within 5-fold, and more preferably within 2- fold, of a value. Where particular values are described in the application and claims, unless otherwise stated the term “about” meaning within an acceptable error range for the particular value should be assumed.

[0087] Unless otherwise stated, the term “TCR” should be understood to encompass full TCRs as well as antigen-binding portions or antigen-binding fragments (also called MHC-peptide binding fragments) thereof. In some embodiments, the TCR is an intact or full-length TCR. In some embodiments, the TCR is an antigen-binding portion that is less than a full-length TCR but that binds to a specific antigenic peptide bound to (e.g., in the context of) an MHC molecule, e.g., an MHC-peptide complex. In some cases, an antigen-binding portion or fragment of a TCR can contain only a portion of the structural domains of a full-length or intact TCR, but yet is able to bind the epitope (e.g., MHC-peptide complex) to which the full TCR binds. In some cases, an antigen-binding portion or fragment of a TCR contains the variable domains of a TCR, such as variable a chain and variable P chain of a TCR, sufficient to form a binding site for binding to a specific MHC-peptide complex, such as generally where each chain contains three complementarity determining regions. Polypeptides or proteins having a binding domain which is an antigen-binding domain or is homologous to an antigen-binding domain are included. Complementarity determining region (CDR) grafted TCRs and other humanized TCRs (including CDR modifications and framework region modifications) are also contemplated by these terms. It should be noted that while reference may be made only to immunoglobulin chains e.g., heavy chains and lights chains), the disclosed invention can be applied to multiple otherWSGR Docket No. 50401-806.601 different types of paired sequences, e.g., T cell receptor chain pairs (TCRa and TCRP chains and TCRy and TCR5 chains), and is not limited to immunoglobulins.

[0088] The terms “complementarity determining region,” and “CDR,” synonymous with “hypervariable region” or “HVR,” are known in the art to refer to non-contiguous sequences of amino acids within TCR variable regions, which confer specificity and / or binding affinity to an MHC-peptide complex. In general, there are three CDRs in each alpha chain variable region (CDR-H1, CDR-H2, CDR-H3) and three CDRs in each beta chain variable region (CDR-L1, CDR-L2, CDR-L3). “Framework regions” and “FR” are known in the art to refer to the non- CDR portions of the variable regions of the alpha and beta chains. In general, there are four FRs in each full-length alpha chain variable region (FR-H1, FR-H2, FR-H3, and FR-H4), and four FRs in each full-length beta chain variable region (FR-L1, FR-L2, FR-L3, and FR-L4).

[0089] The term “variable region” or “variable domain” refers to the domain of a TCR alpha, beta, gamma, or delta chain, that is involved in binding the TCR to antigen-MHC complexes. The variable domains of the alpha chain and beta chain (Va and VP, respectively), and the gamma chain and delta chain (Vy and V5, respectively) of a native TCR generally have similar structures, with each domain comprising four conserved framework regions (FRs) and three CDRs. A single Va or VP domain, or Vy or V5 domain, may be sufficient to confer binding specificity to a peptide-MHC complex.

[0090] Also provided herein are TCR fragments, including antigen-binding fragments. In some embodiments, the TCR is an antigen-binding portion thereof, such as a variant of a full-length TCR not containing the transmembrane and / or cytoplasmic region(s) thereof, which may be referred to as a full soluble TCR. In some embodiments, the TCR is a dimeric TCR (dTCR). In some embodiments, the TCR is a single-chain TCR (scTCR), such as a scTCR having a structure as described in PCT patent publication numbers W02003 / 020763, W02004 / 033685, or WO2011 / 044186. In certain embodiments, the TCR is a single-chain TCR fragment comprising an alpha chain variable region linked to a beta chain variable region, such as a scTv. In some embodiments, a scTv is also referred to as a scFv. A single-chain Tv or scTv refers in some aspects TCR fragments that comprise the variable alpha or gamma chain (Va or Vy) and variable beta or delta chain (VP or V5) domains of a TCR, wherein these domains are present in a single polypeptide chain. Generally, the Tv polypeptide further comprises a polypeptide linker between the Va and VP domains or Vy and V5 domains which enables the scTv to form the desired structure for antigen binding. A diabody refers in some aspects to TCR fragments with two antigen-binding sites, which fragments comprise a Va connected to a VP in the same polypeptide chain (Va-VP) or a Vy connected to a V5 in the same polypeptide chain (Vy-V5). By using a linker that is too short to allow pairing between the two domains on the same chain,WSGR Docket No. 50401-806.601 the domains are forced to pair with the complementary domains of another chain and create two antigen-binding sites. Exemplary diabodies are described more fully in, for example, EP404097 and WO93111161. Fv refers in some aspects to a TCR fragment which contains a complete peptide-MHC complex recognition and peptide-MHC complex binding site. This region consists of a dimer of one TCRa chain and one TCRP chain or one TCRy chain and one TCR5 chain in tight, non-covalent association. It is in this configuration that the three CDRs of each variable domain interact to define a peptide-MHC complex binding site on the surface of the Va-VP dimer or Vy-V5 dimer. Collectively, a combination of one or more of the CDRs from each of the Va-VP chains or Vy-V5 chains confers peptide-MHC complex binding specificity to the TCR. For example, it would be understood that, for example, the CDRa3 and CDRP3 or CDRy3 and CDR53 could be sufficient to confer antigen-binding specificity to a TCR when transferred to Va and VP chains or Vy-V5 chains of a recipient selected TCR or antigen-binding fragment thereof and this combination of CDRs can be tested for binding, affinity, etc. Furthermore, although the two domains of a Tv fragment (Va and VP or Vy and V5 ), are coded for by separate genes, they can be joined using recombinant methods by a synthetic linker that enables them to be made as a single protein chain in which the Va and VP or Vy and V5 chain regions pair to form monovalent molecules (known as single chain Tv (scTv). Such scTvs are also intended to be encompassed within the peptide-MHC complex binding portion of a TCR.

[0091] Among the provided TCRs are humanized and human TCRs. A “humanized” TCR is a TCR in which all or substantially all CDR amino acid residues are derived from non-human CDRs and all or substantially all FR amino acid residues are derived from human FRs. A humanized TCR optionally may include at least a portion of a TCR constant region derived from a human TCR. A “humanized form” of a non-human TCR, refers to a variant of the non-human TCR that has undergone humanization, typically to reduce immunogenicity to humans, while retaining the specificity and affinity of the parental non-human TCR. In some embodiments, some FR residues in a humanized TCR are substituted with corresponding residues from a non- human TCR (e.g., the TCR from which the CDR residues are derived), e.g., to restore or improve TCR specificity or affinity. A “human TCR” is a TCR with an amino acid sequence corresponding to that of a TCR produced by a human or a human cell, or non-human source that utilizes human TCR repertoires or other human TCR-encoding sequences, including human TCR libraries. The term excludes humanized forms of non-human TCRs comprising non-human peptide-MHC complex binding regions, such as those in which all or substantially all CDRs are non-human. Human TCRs may be prepared by administering an immunogen to a transgenic animal that has been modified to produce intact human TCRs or intact TCRs with human variable regions in response to antigenic challenge. Such animals typically contain all or aWSGR Docket No. 50401-806.601 portion of the human TCR loci, which replace the endogenous TCR loci, or which are present extrachromosomally or integrated randomly into the animal’s chromosomes. In such transgenic animals, the endogenous TCR loci have generally been inactivated. Human TCRs also may be derived from human TCR libraries, including phage display and cell-free libraries, containing TCR-encoding sequences derived from a human repertoire.

[0092] The term “cancer neoantigen” or “neoantigen” or “neoepitope” can refer to antigens that are not encoded in a normal, non-mutated host genome. A neoantigen can relate to an antigen including one or more amino acid modifications compared to the parental antigen. For example, a neoantigen may be a tumor-associated neoantigen, wherein the term “tumor-associated neoantigen” can include a peptide or protein including amino acid modifications due to tumorspecific mutations. In some instances, a neoantigen represents either oncogenic viral proteins or abnormal proteins that arise as a consequence of somatic mutations. For example, a neoantigen can arise by the disruption of cellular mechanisms through the activity of viral proteins. Another example can be an exposure of a carcinogenic compound, which in some cases can lead to a somatic mutation. This somatic mutation can ultimately lead to the formation of a tumor / cancer. A neoantigen can be a class of tumor antigens which arise from tumor-specific changes in proteins. Neoantigens encompass, but are not limited to, tumor antigens which arise from, for example, a substitution in a protein sequence, a frame shift mutation, a fusion polypeptide, an inframe deletion, an insertion, and expression of an endogenous retroviral polypeptide. A neoepitope can be an epitope that is not present in a reference, such as a non-diseased cell, e.g., a non-cancerous cell or a germline cell, but is found in a diseased cell, e.g., a cancer cell. This includes situations where a corresponding epitope is found in a normal non-diseased cell or a germline cell but, due to one or more mutations in a diseased cell, e.g., a cancer cell, the sequence of the epitope is changed so as to result in the neoepitope.

[0093] An “epitope” refers in some aspects to a portion of an antigen or other macromolecule capable of forming a binding interaction with the variable region binding pocket of a TCR. In some aspects, an epitope refers to a portion of a peptide-MHC complex capable of forming a binding interaction with the variable region binding pocket of a TCR. Such binding interactions can be manifested as an intermolecular contact with one or more amino acid residues of one or more CDRs. Peptide-MHC complex binding can involve, for example, a CDR3, a CDR3 pair, or in some instances, interactions of up to all six CDRs of the Va and VP chains or Vy or V5 chains. An epitope can be a linear peptide sequence (e.g., “continuous”) or can be composed of noncontiguous amino acid sequences (e.g., “conformational” or “discontinuous”). A TCR can recognize one or more amino acid sequences. Therefore, an epitope can define more than one distinct amino acid sequence. In some aspects, a TCR can recognize one or more amino acidWSGR Docket No. 50401-806.601 sequences or epitopes in the context of an MHC. Epitopes recognized by TCRs can be determined by peptide mapping and sequence analysis techniques well known to one of skill in the art. Binding interactions are manifested as intermolecular contacts with one or more amino acid residues of a CDR. An epitope can refer to an antigenic determinant in a molecule such as an antigen, e.g., to a part in or fragment of the molecule that is recognized by the immune system, for example, that is recognized by a T cell, in particular when presented in the context of MHC molecules. An epitope of a protein such as a tumor antigen can comprise a continuous or discontinuous portion of the protein and can be between 5 and 100, 5 and 50, 8 and 30, or 10 and 25 amino acids in length, for example, the epitope may be 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 21, 22, 23, 24 or 25 amino acids in length.

[0094] The term “binding” refers to a direct association between two molecules, due to, for example, covalent, electrostatic, hydrophobic, and ionic and / or hydrogen-bond interactions under physiological conditions, and includes interactions such as salt bridges and water bridges, as well as any other conventional means of binding.

[0095] In some embodiments, reference to a TCR with “specific binding” refers to a situation in which a TCR will not show any significant binding to molecules other than the peptide-MHC complex containing the epitope recognized by the TCR. The term is also applicable where for example, an antigen binding domain is specific for a particular epitope which is carried by a number of peptide-MHC complexes, in which case the selected TCR or peptide-MHC complex binding fragment thereof carrying the peptide-MHC complex binding domain will be able to bind to the various peptide-MHC complexes carrying the epitope. The terms “preferentially binds” or “specifically binds” mean that the TCRs or fragments thereof bind to an epitope with greater affinity than it binds unrelated amino acid sequences, and, if cross-reactive to other polypeptides containing the epitope, are not toxic at the levels at which they are formulated for administration to human use. In one aspect, such affinity is at least 1-fold greater, at least 2-fold greater, at least 3 -fold greater, at least 4-fold greater, at least 5-fold greater, at least 6-fold greater, at least 7-fold greater, at least 8-fold greater, at least 9-fold greater, 10-fold greater, at least 20-fold greater, at least 30-fold greater, at least 40-fold greater, at least 50-fold greater, at least 60-fold greater, at least 70-fold greater, at least 80-fold greater, at least 90-fold greater, at least 100-fold greater, or at least 1000-fold greater than the affinity of the TCR or fragment thereof for unrelated amino acid sequences.

[0096] The term “affinity” refers to a measure of the strength of binding between two members of a binding pair (e.g., a human leukocyte antigen (HLA)-binding peptide and a class I or II HLA, or a peptide-HLA complex and a T cell receptor (TCR)). Affinity can be expressed as an equilibrium constant of the reversible binding of two agents and can be expressed as KD, KA, K0fWSGR Docket No. 50401-806.601 or Kon. Ko refers to the dissociation constant between two members of a binding pair and has units of molarity. KA refers to the affinity constant between two members of a binding pair is the inverse of the dissociation constant. Affinity may be determined experimentally, for example by surface plasmon resonance (SPR) using commercially available Biacore SPR units. AOff refers to the off-rate constant of two members of a binding pair, (e.g., the off-rate constant of an HLA- binding peptide and a class I or II HLA, or a peptide-HLA complex and a TCR). Koarefers to the on-rate constant of two members of a binding pair, (e.g., the on -rate constant of an HLA-binding peptide and a class I or II HLA, or a peptide-HLA complex and a TCR). Affinity of a binding protein to a ligand such as affinity of a TCR for an epitope can be, for example, from about 100 nanomolar (nM) to about 0.1 nM, from about 100 nM to about 1 picomolar (pM), or from about 100 nM to about 1 femtomolar (fM).

[0097] The term “avidity” refers to the resistance of a complex of two or more agents to dissociation after dilution.

[0098] Throughout this disclosure, “binding data” results may be expressed in terms of an “IC50 ” Affinity may also be expressed as the inhibitory concentration 50 (IC50), or the concentration at which 50% of a first member of a binding pair (e.g., a peptide) is displaced. Likewise, In(ICso) refers to the natural log of the IC50. For example, an IC50 may be the concentration of a tested peptide in a binding assay at which 50% inhibition of binding of a labeled reference peptide is observed. Given the conditions in which the assays are run (e.g., limiting HLA protein concentrations and / or labeled reference peptide concentrations), these values can approximate AD values. Assays for determining binding are well known in the art and are described in detail, for example, in PCT publications WO 94 / 20127 and WO 94 / 03205, and other publications such as Sidney et al., Current Protocols in Immunology 18.3.1 (1998);Sidney, et al., J. Immunol. 154:247 (1995); and Sette, et al., Mol. Immunol. 31 :813 (1994). Alternatively, binding can be expressed relative to binding by a reference standard peptide. Binding can also be determined using other assay systems including those using: live cells (e.g., Ceppellini et al., Nature 339:392 (1989); Christnick et al., Nature 352:67 (1991); Busch et al., Int. Immunol. 2:443 (1990); Hill et al., J. Immunol. 147: 189 (1991); del Guercio et al., J. Immunol. 154:685 (1995)), cell free systems using detergent lysates (e.g., Cerundolo et al., J. Immunol. 21 :2069 (1991)), immobilized purified MHC (e.g., Hill et al., J. Immunol. 152, 2890 (1994); Marshall et al., J. Immunol. 152:4946 (1994)), ELISA systems (e.g., Reay et al., EMBO J. 11 :2829 (1992)), surface plasmon resonance (e.g., Khilko et al., J. Biol. Chem. 268: 15425 (1993)); high flux soluble phase assays (Hammer et al., J. Exp. Med. 180:2353 (1994)), and measurement of class I MHC stabilization or assembly (e.g., Ljunggren et al., Nature 346:476WSGR Docket No. 50401-806.601(1990); Schumacher et al., Cell 62:563 (1990); Townsend et al., Cell 62:285 (1990); Parker et al., J. Immunol. 149: 1896 (1992)).

[0099] The terms “major histocompatibility complex” and the abbreviation “MHC” can include MHC class I and MHC class II molecules and relate to a complex of genes which occurs in all vertebrates. MHC proteins or molecules can be important for signaling between lymphocytes and antigen presenting cells or diseased cells in immune reactions, wherein the MHC proteins or molecules bind peptides and present them for recognition by T cell receptors. The proteins encoded by the MHC can be expressed on the surface of cells, and display both self-antigens (peptide fragments from the cell itself) and non-self-antigens (e.g., fragments of invading microorganisms) to a T cell. The MHC region can be divided into three subgroups, class I, class II, and class III. MHC class I proteins can contain an a-chain and P2-microglobulin (not part of the MHC encoded by chromosome 15). They can present antigen fragments to cytotoxic T cells. MHC class II proteins can contain a- and P-chains and they can present antigen fragments to T- helper cells. MHC class III region can encode for other immune components, such as complement components and cytokines. The MHC can be both polygenic (there are several MHC class I and MHC class II genes) and polymorphic (there are multiple alleles of each gene).

[0100] The term “haplotype” can refer to the human leukocyte antigen (HLA) alleles found on one chromosome and the proteins encoded thereby. Haplotype may also refer to the allele present at any one locus within the MHC. Each class of MHC is represented by several loci: e.g., HLA-A (Human Leukocyte Antigen-A). HLA-B, HLA-C, HLA-E, HLA-F, HLA-G, HLA-H, HLA- J, HLA-K, HLA-L, HLA-P and HLA-V for class I and HLA-DRA, HLA-DRB1-9, HLA- DQA1, HLA-DQB1, HLA-DPA1, HLA-DPB1, HLA-DPB2, HLA-DMA, HLA-DMB, HLA- DOA, and HLA-DOB for class II. The terms “HLA allele” and “MHC allele” are used interchangeably herein.

[0101] The terms “polynucleotide,” “nucleotide”, “nucleotide sequence”, “nucleic acid” and “oligonucleotide” are used interchangeably. They can refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof. Polynucleotides may have any three dimensional structure, and may perform any function, known or unknown. The following are non-limiting examples of polynucleotides: coding or non-coding regions of a gene or gene fragment, loci (locus) defined from linkage analysis, exons, introns, messenger RNA (mRNA), transfer RNA (tRNA), ribosomal RNA (rRNA), short interfering RNA (siRNA), short-hairpin RNA (shRNA), micro-RNA (miRNA), ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. A polynucleotide may comprise one or more modified nucleotides, such as methylated nucleotides and nucleotideWSGR Docket No. 50401-806.601 analogs. If present, modifications to the nucleotide structure may be imparted before or after assembly of the polymer. Polynucleotides can include nonstandard nucleotides, such as nucleotide analogs or modified nucleotides. In some embodiments, nonstandard nucleotides can stabilize hybrid formation. In some embodiments, nonstandard nucleotides can destabilize hybrid formation. In some embodiments, nonstandard nucleotides can enhance hybridization specificity. In some embodiments, nonstandard nucleotides can reduce hybridization specificity. Examples of nonstandard nucleotide modifications include 2’ O-Me, 2’ O-allyl, 2’ O-propargyl, 2’ O-alkyl, 2’ fluoro, 2’ arabino, 2’ xylo, 2’ fluoro arabino, phosphorothioate, phosphorodithioate, phosphoroamidates, 2’ Amino, 5-alkyl-substituted pyrimidine, 3’ deoxyguanosine, 5-halo-substituted pyrimidine, alkyl-substituted purine, halo-substituted purine, bicyclic nucleotides, 2’MOE, PNA molecules, LNA-molecules, LNA-like molecules, diaminopurine, S2T, 5 -fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 5-(carboxyhydroxylmethyl)uracil, 5-carboxymethylaminomethyl-2- thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1 -methylinosine, 2,2-dimethylguanine, 2- methyladenine, 2-methylguanine, 3 -methylcytosine, 5-methylcytosine, bf’-adenine, 7-methyl guanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D- mannosylqueosine, 5’ - methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-D46- isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2- thiocytosine, 5- methyl-2 -thiouracil, 2-thiouracil, 4-thiouracil, 5 -methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxy acetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2- carboxypropyl) uracil, (acp3)w, 2,6-diaminopurine, and derivatives thereof. The sequence of nucleotides may be interrupted by non-nucleotide components. A polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component.

[0102] “Complementarity” can refer to the ability of a nucleic acid to form hydrogen bond(s) with another nucleic acid sequence by either traditional Watson-Crick or other non-traditional types. A percent complementarity can indicate the percentage of residues in a nucleic acid molecule which can form hydrogen bonds (e.g., Watson-Crick base pairing) with a second nucleic acid sequence (e.g., 5, 6, 7, 8, 9, 10 out of 10 being 50%, 60%, 70%, 80%, 90%, and 100% complementary, respectively). “Perfectly complementary” can mean that all the contiguous residues of a nucleic acid sequence will hydrogen bond with the same number of contiguous residues in a second nucleic acid sequence. “Substantially complementary” refers to a degree of complementarity that is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% over a region of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, or more nucleotides, or can refer to two nucleic acids that hybridizeWSGR Docket No. 50401-806.601 under stringent conditions. Sequence identity, such as for the purpose of assessing percent complementarity, may be measured by any suitable alignment algorithm, including but not limited to the Needleman-Wunsch algorithm (e.g., the EMBOSS Needle aligner available at www.ebi.ac.uk / Tools / psa / emboss_needle / nucleotide.html, optionally with default settings), the BLAST algorithm (see e.g., the BLAST alignment tool available at blast.ncbi.nlm.nih.gov / Blast.cgi, optionally with default settings), or the Smith- Waterman algorithm. Optimal alignment may be assessed using any suitable parameters of a chosen algorithm, including default parameters.

[0103] The terms “polypeptide” and “protein” are used interchangeably to refer to a polymer of amino acid residues, and are not limited to a minimum length. For example, a polypeptide can comprise at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 peptides or amino acids. Examples of polypeptides include, but are not limited to, amino acid chains, proteins, peptides, hormones, polypeptide saccharides, lipids, glycolipids, phospholipids, antibodies, enzymes, kinases, receptors, transcription factors, and ligands. Polypeptides, including the provided TCRs and TCR chains and other peptides, e.g., linkers and binding peptides, may include amino acid residues including natural and / or non-natural amino acid residues. The terms also include postexpression modifications of the polypeptide, for example, glycosylation, sialylation, acetylation, phosphorylation, and the like. In some aspects, the polypeptides may contain modifications with respect to a native or natural sequence, as long as the protein maintains the desired activity. These modifications may be deliberate, as through site-directed mutagenesis, or may be accidental, such as through mutations of hosts which produce the proteins or errors due to PCR amplification.

[0104] As used herein, the twenty conventional amino acids and their abbreviations known to one skilled in the art follow conventional usage. Stereoisomers (e.g., D-amino acids) of the twenty conventional amino acids, unnatural amino acids such as a-, a-di substituted amino acids, N-alkyl amino acids, lactic acid, and other unconventional amino acids may also be suitable components for polypeptides of the present invention. Examples of unconventional amino acids include: 4-hydroxyproline, y-carboxyglutamate, s-N,N,N-trimethyllysine, s-N-acetyllysine, O- phosphoserine, N-acetylserine, N-formylmethionine, 3 -methylhistidine, 5-hydroxylysine, o-N- methylarginine, and other similar amino acids and imino acids (e.g., 4-hydroxyproline). In the polypeptide notation used herein, the left hand direction is the amino terminal direction and the right hand direction is the carboxy-terminal direction, in accordance with standard usage and convention. Percent (%) sequence identity with respect to a reference polypeptide sequence (or nucleic acid sequence) is the percentage of amino acid residues (or nucleotides in case of nucleicWSGR Docket No. 50401-806.601 acid sequence) in a candidate sequence that are identical with the amino acid residues (or nucleotides) in the reference polypeptide sequence (or nucleic acid sequence), after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. For purposes herein, however, % amino acid sequence identity values are generated using the sequence comparison computer program ALIGN-2. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc., and the source code has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available from Genentech, Inc., South San Francisco, Calif., or may be compiled from the source code. The ALIGN-2 program should be compiled for use on a UNIX operating system, including digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary. In situations where ALIGN-2 is employed for amino acid sequence comparisons, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows: 100 times the fraction X / Y, where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A. Unless specifically stated otherwise, all % amino acid sequence identity values used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program.

[0105] A “subject,” “individual”, “host” or “patient” refers to living organisms such as mammals. Examples of subjects and hosts include, but are not limited to, horses, cows, camels, sheep, pigs, goats, dogs, cats, rabbits, guinea pigs, rats, mice (e.g., humanized mice), gerbils, non-human primates (e.g., macaques), humans and the like, non-mammals, including, e.g., nonmammalian vertebrates, such as birds (e.g., chickens or ducks) fish (e.g., sharks) or frogs (e.g., Xenopus), and non-mammalian invertebrates, as well as transgenic species thereof. In certainWSGR Docket No. 50401-806.601 aspects, a subject refers to a single organism (e.g., human). In certain aspects, or a group of individuals composing a small cohort having either a common immune factor to study and / or disease, and / or a cohort of individuals without the disease (e.g., negative / normal control) are provided. A subject from whom samples are obtained can either be inflicted with a disease and / or disorder e.g., one or more allergies, infections, cancers or autoimmune disorders or the like) and can be compared against a negative control subject which is not affected by the disease.

[0106] A “kit” refers to a delivery system for delivering materials or reagents for carrying out a method disclosed herein. In some embodiments, kits include systems that allow for the storage, transport, or delivery of reaction reagents (e.g., probes, enzymes, etc. in the appropriate containers) and / or supporting materials (e.g., buffers, written instructions for performing the assay etc.) from one location to another. For example, kits include one or more enclosures (e.g., boxes) containing the relevant reaction reagents and / or supporting materials. Such contents may be delivered to the intended recipient together or separately. For example, a first container may contain an enzyme for use in an assay, while a second container contains a plurality of primers. A packaging material refers to a physical structure housing the components of the kit. The packaging material can maintain the components sterilely and can be made of material commonly used for such purposes (e.g., paper, corrugated fiber, glass, plastic, foil, ampules, etc.). The label or packaging insert can include appropriate written instructions. Kits, therefore, can additionally include labels or instructions for using the kit components in any method of the invention. A kit can include a compound in a pack, or dispenser together with instructions for administering the compound in a method described herein.T Cell Receptors (TCRs)

[0107] Disclosed herein are T cell receptors (TCRs) and recombinant nucleic acids encoding the same. In some aspects, provided herein is a recombinant nucleic acid encoding a TCR comprising a TCR beta and a TCR alpha chain that recognizes epitopes (e.g., E7 epitope from human papillomavirus) in complex with a human MHC.

[0108] The ability of T cells to recognize antigens associated with infectious organisms or cancers is conferred by its TCR, which is made up of both an alpha (a) chain and a beta (P) chain or a gamma (y) and a delta (5) chain. The proteins which make up these chains are encoded by DNA, which employs a unique mechanism for generating the diversity of the TCR. This multi-subunit immune recognition receptor can associate with the CD3 complex and bind peptides presented by the MHC class I and II proteins on the surface of antigen-presenting cells (APCs). The first signal in activation of T cells can be provided by binding of the T-cell receptor to a short peptide presented by the MHC on another cell. This ensures that only a T cell with aWSGR Docket No. 50401-806.601TCR specific to that peptide is activated. The partner cell is usually an antigen-presenting cell such as a professional antigen-presenting cell, usually a dendritic cell in the case of naive responses, although B-cells and macrophages can be important APCs. Binding of a TCR to the antigenic peptide on the APC can be a central event in T cell activation, which occurs at an immunological synapse at the point of contact between the T cell and the APC.

[0109] Each TCR can comprise variable complementarity determining regions (CDRs), as well as framework regions (FRs) and a constant region. The TCR described herein may be in soluble form. The TCR described herein may not comprise a constant region. For example, in some embodiments, TCR does not comprise a TCR alpha constant domain, a TCR beta constant domain, or both. The TCR described herein may comprise a functional fragment of a full-length TCR. In some embodiments, the TCR disclosed herein comprises a TCR alpha constant domain and / or a TCR beta constant domain. The TCR described herein may comprise the variable region of the alpha chain or beta chain only. The amino acid sequence of the third complementarity-determining region (CDR3) loops of the alpha (or a) and beta (or P) chain variable domains largely determines the sequence diversity of aP T cells arising from recombination between variable (VP), diversity (DP), and joining (JP) gene segments in the P chain locus, and between analogous Va and Ja gene segments in the a chain locus, respectively. The existence of multiple such gene segments in the TCR a and P chain loci allows for a large number of distinct CDR3 sequences to be encoded. Independent addition and deletion of nucleotides at the VP-DP, Dp-jp, and Va-Ja junctions during the process of TCR gene rearrangement further increases CDR3 sequence diversity. In this respect, immunocompetence is reflected in the diversity of TCRs. The y5 TCR is distinctive from the aP TCR in that it encodes a receptor that interacts closely with the innate immune system. TCRyS, is expressed early in development, has specialized anatomical distribution, has unique pathogen and small-molecule specificities, and has a broad spectrum of innate and adaptive cellular interactions. Early in ontogeny, as the restricted subsets of TCRyS cells populate various tissues prenatally, a biased pattern of TCRy V and J segment expression is established. In some embodiments, the TCR disclosed herein is a membrane-bound TCR.

[0110] In some embodiments, the TCRs disclosed herein can bind to a peptide: MHC complex. In some cases, the TCR can bind to an MHC peptide complex comprising an epitope from an antigen or candidate antigen described herein. In some cases, the TCR can bind to an MHC peptide complex comprising an epitope of protein encoded by the genome of a cancer cell. The binding of the TCR complex and the epitope bound with the MHC molecule (e.g., MHC class I or MHC class II) can trigger signal transduction pathways that lead to regulation of immune responses against the antigenic peptide. In some embodiments, the TCR disclosed herein bindsWSGR Docket No. 50401-806.601 to an MHC-peptide complex with a KD or an IC50 of 1 pM to 1 nM. In some embodiments, the TCR disclosed herein binds to an MHC-peptide complex with a KD or an IC50 of less than 500 nM, 250 nM, 150 nM, 100 nM, 50 nM, 25 nM or 10 nM. In some embodiments, the TCR disclosed herein binds to an MHC-peptide complex with a KD or an IC50 of less than 500 nM. In some embodiments, the TCR disclosed herein binds to an MHC-peptide complex with a KD or an IC50 of less than 250 nM. In some embodiments, the TCR disclosed herein binds to an MHC- peptide complex with a KD or an IC50 of less than 150 nM. In some embodiments, the TCR disclosed herein binds to an MHC-peptide complex with a KD or an IC50 of less than 100 nM. In some embodiments, the TCR disclosed herein binds to an MHC-peptide complex with a KD or an IC50 of less than 50 nM. In some embodiments, the TCR disclosed herein binds to an MHC- peptide complex with a KD or an IC50 of less than 25 nM. In some embodiments, the TCR disclosed herein binds to an MHC-peptide complex with a KD or an IC50 of less than 10 nM. In some embodiments, the TCR disclosed herein binds to an E7 epitope from HPV in complex with the human encoded by the HLA-A*02:01 allele with a KD of at least 500 nM, at least 250 nM, at least 50 nM, at least 25 nM, at least 10 nM, or at least 5 nM. In some embodiments, the TCR disclosed herein binds to an E7 epitope from HPV in complex with the human encoded by the HLA-A*02:01 allele with a KD of at most 500 nM, at most 250 nM, at most 50 nM, at most 25 nM, at most 10 nM, or at most 5 nM. In some embodiments, the TCR disclosed herein binds to an E7 epitope from HPV in complex with the human encoded by the HLA-A*02:01 allele with a KD of at least 500 nM, at least 250 nM, at least 50 nM, at least 25 nM, at least 10 nM, or at least 5 nM. In some embodiments, the TCR disclosed herein binds to an E7 epitope from HPV in complex with the human encoded by the HLA-A*02:01 allele with a KD of at most 500 nM, at most 250 nM, at most 50 nM, at most 25 nM, at most 10 nM, or at most 5 nM.[OlH] In some embodiments, the TCR disclosed herein binds to an E7 epitope from human papillomavirus (HPV) in complex with a human MHC encoded by an HLA-A*02:01 allele with an EC50 of more than 0.2 nM. In some embodiments, the TCR disclosed herein binds to an E7 epitope from human papillomavirus (HPV) in complex with a human MHC encoded by an HLA-A*02:01 allele with an EC50 of more than 0.2 nM and less than 50 nM. In some embodiments, the TCR disclosed herein binds to an E7 epitope from human papillomavirus (HPV) in complex with a human MHC encoded by an HLA-A*02:01 allele with an EC50 of more than 0.2 nM and less than 100 nM. In some embodiments, the TCR disclosed herein binds to an E7 epitope from human papillomavirus (HPV) in complex with a human MHC encoded by an HLA-A*02:01 allele with an EC50 of more than 0.5 nM and less than 15 nM. In some embodiments, the TCR disclosed herein binds to an E7 epitope from human papillomavirus (HPV) in complex with a human MHC encoded by an HLA-A*02:01 allele with an EC50 ofWSGR Docket No. 50401-806.601 more than 0.2 nM. In some embodiments, the TCR disclosed herein binds to an E7 epitope from human papillomavirus (HPV) in complex with a human MHC encoded by an HLA-A*02:01 allele with an EC50 of more than 12 nM. In some embodiments, the TCR disclosed herein binds to an E7 epitope from human papillomavirus (HPV) in complex with a human MHC encoded by an HLA-A*02:01 allele with an EC50 as set forth in Table 2.

[0112] In some embodiments, the TCR disclosed herein binds to an E7 epitope from HPV in complex with a human MHC encoded by an HLA-A*02:01 allele, wherein the E7 epitope comprises a sequence of SEQ ID NO: 286.

[0113] In some embodiments, the TCRs described herein may not lead to resistance by a subject being administered with a therapeutic agent comprising the TCRs.

[0114] In some embodiments, the TCR sequence is comprised of human sequences. In some embodiments, the TCR sequence is comprised of non-human animal sequences that have been humanized using any method of humanization known in the art. The TCRs disclosed herein can be engineered TCRs.

[0115] In some aspects, provided herein is a TCR or a recombinant nucleic acid comprising a sequence encoding thereof. In some embodiments, a TCR or a recombinant nucleic acid disclosed herein comprises a sequence encoding thereof comprises a TCR beta chain. In some embodiments, a TCR or a recombinant nucleic acid disclosed herein comprises a sequence encoding thereof comprises a TCR alpha chain.

[0116] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% sequence identity to any one of the amino acid sequences set forth in Table 2. In some embodiments, the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% sequence identity to any one of the amino acid sequences set forth in Table 2. In some embodiments, the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% sequence identity to any one of the amino acid sequences set forth in Table 2. In some embodiments, the TCR beta chain comprises a variable region having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% sequence identity to any one of the amino acid sequences set forth in Table 2. In some embodiments, the TCR alpha chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, atWSGR Docket No. 50401-806.601 least 90%, at least 95%, at least 99%, or 100% sequence identity to any one of the amino acid sequences set forth in Table 2. In some embodiments, the TCR alpha chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% sequence identity to any one of the amino acid sequences set forth in Table 2. In some embodiments, the TCR alpha chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% sequence identity to any one of the amino acid sequences set forth in Table 2. In some embodiments, the TCR alpha chain comprises a variable region having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100% sequence identity to any one of the amino acid sequences set forth in Table 2.

[0117] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 170. In some embodiments, the CDR3 has an amino acid sequence of SEQ ID NO: 170. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 5. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 5. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 6. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 6. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 171. In some embodiments, the TCR beta chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 171. In some embodiments, a TCR alpha chain comprises a CDR3 having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence forth in SEQ ID NO: 168. In some embodiments, the TCR alpha chainWSGR Docket No. 50401-806.601 comprises a CDR3, wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 168. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 166. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 166. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 167. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 167. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 169. In some embodiments, the TCR alpha chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 169.

[0118] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 278. In some embodiments, the CDR3 has an amino acid sequence of SEQ ID NO: 278. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 5. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 5. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 6. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 6. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence setWSGR Docket No. 50401-806.601 forth in SEQ ID NO: 279. In some embodiments, the TCR beta chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 279. In some embodiments, a TCR alpha chain comprises a CDR3 having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence forth in SEQ ID NO: 276. In some embodiments, the TCR alpha chain comprises a CDR3, wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 276. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 17. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 17. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 18. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 18. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 277. In some embodiments, the TCR alpha chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 277.

[0119] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 7. In some embodiments, the CDR3 has an amino acid sequence of SEQ ID NO: 7. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 5. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 5. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acidWSGR Docket No. 50401-806.601 sequence set forth in SEQ ID NO: 6. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 6. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 8. In some embodiments, the TCR beta chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 8. In some embodiments, a TCR alpha chain comprises a CDR3 having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence forth in SEQ ID NO: 3. In some embodiments, the TCR alpha chain comprises a CDR3, wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 3. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 1. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 1. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 2. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 2. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 4. In some embodiments, the TCR alpha chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 4.

[0120] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 15. In some embodiments, the CDR3 has an amino acid sequence of SEQ ID NO: 15. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 13. InWSGR Docket No. 50401-806.601 some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 16. In some embodiments, the TCR beta chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 16. In some embodiments, a TCR alpha chain comprises a CDR3 having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence forth in SEQ ID NO: 11. In some embodiments, the TCR alpha chain comprises a CDR3, wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 11. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 9. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 9. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 10. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 10. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 12. In some embodiments, the TCR alpha chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 12.

[0121] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to anWSGR Docket No. 50401-806.601 amino acid sequence set forth in SEQ ID NO: 15. In some embodiments, the CDR3 has an amino acid sequence of SEQ ID NO: 15. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 16. In some embodiments, the TCR beta chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 16. In some embodiments, a TCR alpha chain comprises a CDR3 having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence forth in SEQ ID NO: 19. In some embodiments, the TCR alpha chain comprises a CDR3, wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 19. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 17. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 17. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 18. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 18. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 20. In some embodiments,WSGR Docket No. 50401-806.601 the TCR alpha chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 20.

[0122] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 28. In some embodiments, the CDR3 has an amino acid sequence of SEQ ID NO: 28. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 26. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 26. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 27. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 27. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 29. In some embodiments, the TCR beta chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 29. In some embodiments, a TCR alpha chain comprises a CDR3 having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence forth in SEQ ID NO: 24. In some embodiments, the TCR alpha chain comprises a CDR3, wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 24. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 21. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 21. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 22. InWSGR Docket No. 50401-806.601 some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 22. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 25. In some embodiments, the TCR alpha chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 25.

[0123] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 32. In some embodiments, the CDR3 has an amino acid sequence of SEQ ID NO: 32. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 33. In some embodiments, the TCR beta chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 33. In some embodiments, a TCR alpha chain comprises a CDR3 having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence forth in SEQ ID NO: 30. In some embodiments, the TCR alpha chain comprises a CDR3, wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 30. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 9. In some embodiments, the TCR alpha chain furtherWSGR Docket No. 50401-806.601 comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 9. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 10. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 10. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 31. In some embodiments, the TCR alpha chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 31.

[0124] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 32. In some embodiments, the CDR3 has an amino acid sequence of SEQ ID NO: 32. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 33. In some embodiments, the TCR beta chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 33. In some embodiments, a TCR alpha chain comprises a CDR3 having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence forth in SEQ ID NO: 34. In some embodiments, the TCR alpha chain comprises aWSGR Docket No. 50401-806.601CDR3, wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 34. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 9. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 9. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 10. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 10. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 35. In some embodiments, the TCR alpha chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 35.

[0125] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 36. In some embodiments, the CDR3 has an amino acid sequence of SEQ ID NO: 36. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence setWSGR Docket No. 50401-806.601 forth in SEQ ID NO: 37. In some embodiments, the TCR beta chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 37. In some embodiments, a TCR alpha chain comprises a CDR3 having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence forth in SEQ ID NO: 34. In some embodiments, the TCR alpha chain comprises a CDR3, wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 34. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 9. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 9. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 10. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 10. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 35. In some embodiments, the TCR alpha chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 35.

[0126] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 44. In some embodiments, the CDR3 has an amino acid sequence of SEQ ID NO: 44. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 42. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 42. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to anWSGR Docket No. 50401-806.601 amino acid sequence set forth in SEQ ID NO: 43. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 43. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 45. In some embodiments, the TCR beta chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 45. In some embodiments, a TCR alpha chain comprises a CDR3 having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence forth in SEQ ID NO: 40. In some embodiments, the TCR alpha chain comprises a CDR3, wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 40. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 38. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 38. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 39. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 39. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 41. In some embodiments, the TCR alpha chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 41.

[0127] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 50. In some embodiments, the CDR3 has an amino acid sequence of SEQ ID NO: 50. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 13. InWSGR Docket No. 50401-806.601 some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 51. In some embodiments, the TCR beta chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 51. In some embodiments, a TCR alpha chain comprises a CDR3 having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence forth in SEQ ID NO: 48. In some embodiments, the TCR alpha chain comprises a CDR3, wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 48. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 46. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 46. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 47. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 47. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 49. In some embodiments, the TCR alpha chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 49.

[0128] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to anWSGR Docket No. 50401-806.601 amino acid sequence set forth in SEQ ID NO: 56. In some embodiments, the CDR3 has an amino acid sequence of SEQ ID NO: 56. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 57. In some embodiments, the TCR beta chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 57. In some embodiments, a TCR alpha chain comprises a CDR3 having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence forth in SEQ ID NO: 54. In some embodiments, the TCR alpha chain comprises a CDR3, wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 54. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 52. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 52. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 53. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 53. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 55. In some embodiments,WSGR Docket No. 50401-806.601 the TCR alpha chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 55.

[0129] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 58. In some embodiments, the CDR3 has an amino acid sequence of SEQ ID NO: 58. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 59. In some embodiments, the TCR beta chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 59. In some embodiments, a TCR alpha chain comprises a CDR3 having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence forth in SEQ ID NO: 54. In some embodiments, the TCR alpha chain comprises a CDR3, wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 54. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 52. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 52. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 53. InWSGR Docket No. 50401-806.601 some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 53. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 55. In some embodiments, the TCR alpha chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 55.

[0130] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 58. In some embodiments, the CDR3 has an amino acid sequence of SEQ ID NO: 58. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 59. In some embodiments, the TCR beta chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 59. In some embodiments, a TCR alpha chain comprises a CDR3 having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence forth in SEQ ID NO: 60. In some embodiments, the TCR alpha chain comprises a CDR3, wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 60. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 9. In some embodiments, the TCR alpha chain furtherWSGR Docket No. 50401-806.601 comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 9. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 10. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 10. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 61. In some embodiments, the TCR alpha chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 61.

[0131] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 66. In some embodiments, the CDR3 has an amino acid sequence of SEQ ID NO: 66. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 67. In some embodiments, the TCR beta chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 67. In some embodiments, a TCR alpha chain comprises a CDR3 having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence forth in SEQ ID NO: 64. In some embodiments, the TCR alpha chain comprises aWSGR Docket No. 50401-806.601CDR3, wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 64. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 62. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 62. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 63. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 63. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 65. In some embodiments, the TCR alpha chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 65.

[0132] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 74. In some embodiments, the CDR3 has an amino acid sequence of SEQ ID NO: 74. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 72. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 72. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 73. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 73. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence setWSGR Docket No. 50401-806.601 forth in SEQ ID NO: 75. In some embodiments, the TCR beta chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 75. In some embodiments, a TCR alpha chain comprises a CDR3 having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence forth in SEQ ID NO: 70. In some embodiments, the TCR alpha chain comprises a CDR3, wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 70. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 68. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 68. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 69. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 69. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 71. In some embodiments, the TCR alpha chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 71.

[0133] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 82. In some embodiments, the CDR3 has an amino acid sequence of SEQ ID NO: 82. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 80. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 80. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to anWSGR Docket No. 50401-806.601 amino acid sequence set forth in SEQ ID NO: 81. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 81. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 83. In some embodiments, the TCR beta chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 83. In some embodiments, a TCR alpha chain comprises a CDR3 having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence forth in SEQ ID NO: 78. In some embodiments, the TCR alpha chain comprises a CDR3, wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 78. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 76. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 76. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 77. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 77. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 79. In some embodiments, the TCR alpha chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 79.

[0134] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 88. In some embodiments, the CDR3 has an amino acid sequence of SEQ ID NO: 88. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 13. InWSGR Docket No. 50401-806.601 some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 89. In some embodiments, the TCR beta chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 89. In some embodiments, a TCR alpha chain comprises a CDR3 having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence forth in SEQ ID NO: 86. In some embodiments, the TCR alpha chain comprises a CDR3, wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 86. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 84. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 84. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 85. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 85. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 87. In some embodiments, the TCR alpha chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 87.

[0135] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to anWSGR Docket No. 50401-806.601 amino acid sequence set forth in SEQ ID NO: 94. In some embodiments, the CDR3 has an amino acid sequence of SEQ ID NO: 94. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 92. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 92. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 93. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 93. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 95. In some embodiments, the TCR beta chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 95. In some embodiments, a TCR alpha chain comprises a CDR3 having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence forth in SEQ ID NO: 90. In some embodiments, the TCR alpha chain comprises a CDR3, wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 90. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 52. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 52. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 53. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 53. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 91. In some embodiments,WSGR Docket No. 50401-806.601 the TCR alpha chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 91.

[0136] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 98. In some embodiments, the CDR3 has an amino acid sequence of SEQ ID NO: 98. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 26. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 26. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 27. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 27. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 99. In some embodiments, the TCR beta chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 99. In some embodiments, a TCR alpha chain comprises a CDR3 having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence forth in SEQ ID NO: 96. In some embodiments, the TCR alpha chain comprises a CDR3, wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 96. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 17. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 17. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 18. InWSGR Docket No. 50401-806.601 some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 18. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 97. In some embodiments, the TCR alpha chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 97.

[0137] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 106. In some embodiments, the CDR3 has an amino acid sequence of SEQ ID NO: 106. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 104. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 104. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 105. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 105. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 107. In some embodiments, the TCR beta chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 107. In some embodiments, a TCR alpha chain comprises a CDR3 having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence forth in SEQ ID NO: 102. In some embodiments, the TCR alpha chain comprises a CDR3, wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 102. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 100. In some embodiments, theWSGR Docket No. 50401-806.601TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 100. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 101. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 101. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 103. In some embodiments, the TCR alpha chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 103.

[0138] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 112. In some embodiments, the CDR3 has an amino acid sequence of SEQ ID NO: 112. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 113. In some embodiments, the TCR beta chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 113. In some embodiments, a TCR alpha chain comprises a CDR3 having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence forth in SEQ ID NO: 110. In some embodiments, the TCR alpha chainWSGR Docket No. 50401-806.601 comprises a CDR3, wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 110. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 108. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 108. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 109. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 109. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 111. In some embodiments, the TCR alpha chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 111.

[0139] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 118. In some embodiments, the CDR3 has an amino acid sequence of SEQ ID NO: 118. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 5. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 5. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 6. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 6. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence setWSGR Docket No. 50401-806.601 forth in SEQ ID NO: 119. In some embodiments, the TCR beta chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 119. In some embodiments, a TCR alpha chain comprises a CDR3 having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence forth in SEQ ID NO: 116. In some embodiments, the TCR alpha chain comprises a CDR3, wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 116. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 114. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 114. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 115. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 115. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 117. In some embodiments, the TCR alpha chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 117.

[0140] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 124. In some embodiments, the CDR3 has an amino acid sequence of SEQ ID NO: 124. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 26. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 26. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to anWSGR Docket No. 50401-806.601 amino acid sequence set forth in SEQ ID NO: 27. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 27. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 125. In some embodiments, the TCR beta chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 125. In some embodiments, a TCR alpha chain comprises a CDR3 having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence forth in SEQ ID NO: 122. In some embodiments, the TCR alpha chain comprises a CDR3, wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 122. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 120. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 120. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 121. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 121. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 123. In some embodiments, the TCR alpha chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 123.

[0141] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 130. In some embodiments, the CDR3 has an amino acid sequence of SEQ ID NO: 130. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 14. InWSGR Docket No. 50401-806.601 some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 130. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 130. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 131. In some embodiments, the TCR beta chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 131. In some embodiments, a TCR alpha chain comprises a CDR3 having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence forth in SEQ ID NO: 128. In some embodiments, the TCR alpha chain comprises a CDR3, wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 128. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 126. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 126. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 127. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 127. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 129. In some embodiments, the TCR alpha chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 129.

[0142] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to anWSGR Docket No. 50401-806.601 amino acid sequence set forth in SEQ ID NO: 134. In some embodiments, the CDR3 has an amino acid sequence of SEQ ID NO: 134. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 135. In some embodiments, the TCR beta chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 135. In some embodiments, a TCR alpha chain comprises a CDR3 having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence forth in SEQ ID NO: 132. In some embodiments, the TCR alpha chain comprises a CDR3, wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 132. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 84. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 84. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 85. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 85. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ IDWSGR Docket No. 50401-806.601NO: 133. In some embodiments, the TCR alpha chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 133.

[0143] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 138. In some embodiments, the CDR3 has an amino acid sequence of SEQ ID NO: 138. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 139. In some embodiments, the TCR beta chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 139. In some embodiments, a TCR alpha chain comprises a CDR3 having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence forth in SEQ ID NO: 136. In some embodiments, the TCR alpha chain comprises a CDR3, wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 136. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 52. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 52. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth inWSGR Docket No. 50401-806.601SEQ ID NO: 53. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 53. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 137. In some embodiments, the TCR alpha chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 137.

[0144] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 142. In some embodiments, the CDR3 has an amino acid sequence of SEQ ID NO: 142. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 143. In some embodiments, the TCR beta chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 143. In some embodiments, a TCR alpha chain comprises a CDR3 having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence forth in SEQ ID NO: 140. In some embodiments, the TCR alpha chain comprises a CDR3, wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 140. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 9. In some embodiments, the TCRWSGR Docket No. 50401-806.601 alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 9. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 10. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 10. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 141. In some embodiments, the TCR alpha chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 141.

[0145] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 146. In some embodiments, the CDR3 has an amino acid sequence of SEQ ID NO: 146. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 26. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 26. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 27. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 27. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 147. In some embodiments, the TCR beta chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 147. In some embodiments, a TCR alpha chain comprises a CDR3 having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence forth in SEQ ID NO: 144. In some embodiments, the TCR alpha chainWSGR Docket No. 50401-806.601 comprises a CDR3, wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 144. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 17. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 17. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 18. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 18. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 145. In some embodiments, the TCR alpha chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 145.

[0146] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 150. In some embodiments, the CDR3 has an amino acid sequence of SEQ ID NO: 150. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence setWSGR Docket No. 50401-806.601 forth in SEQ ID NO: 151. In some embodiments, the TCR beta chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 151. In some embodiments, a TCR alpha chain comprises a CDR3 having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence forth in SEQ ID NO: 148. In some embodiments, the TCR alpha chain comprises a CDR3, wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 148. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 52. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 52. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 53. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 53. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 149. In some embodiments, the TCR alpha chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 149.

[0147] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 154. In some embodiments, the CDR3 has an amino acid sequence of SEQ ID NO: 154. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to anWSGR Docket No. 50401-806.601 amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 144. In some embodiments, the TCR beta chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 144. In some embodiments, a TCR alpha chain comprises a CDR3 having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence forth in SEQ ID NO: 152. In some embodiments, the TCR alpha chain comprises a CDR3, wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 152. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 52. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 52. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 53. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 53. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 153. In some embodiments, the TCR alpha chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 153.

[0148] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 158. In some embodiments, the CDR3 has an amino acid sequence of SEQ ID NO: 158. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 13. InWSGR Docket No. 50401-806.601 some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 159. In some embodiments, the TCR beta chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 159. In some embodiments, a TCR alpha chain comprises a CDR3 having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence forth in SEQ ID NO: 156. In some embodiments, the TCR alpha chain comprises a CDR3, wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 156. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 9. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 9. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 10. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 10. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 157. In some embodiments, the TCR alpha chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 157.

[0149] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to anWSGR Docket No. 50401-806.601 amino acid sequence set forth in SEQ ID NO: 164. In some embodiments, the CDR3 has an amino acid sequence of SEQ ID NO: 164. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 72. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 72. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 73. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 73. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 165. In some embodiments, the TCR beta chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 165. In some embodiments, a TCR alpha chain comprises a CDR3 having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence forth in SEQ ID NO: 162. In some embodiments, the TCR alpha chain comprises a CDR3, wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 162. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 160. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 160. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 161. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 161. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ IDWSGR Docket No. 50401-806.601NO: 163. In some embodiments, the TCR alpha chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 163.

[0150] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 174. In some embodiments, the CDR3 has an amino acid sequence of SEQ ID NO: 174. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 5. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 5. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 6. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 6. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 175. In some embodiments, the TCR beta chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 175. In some embodiments, a TCR alpha chain comprises a CDR3 having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence forth in SEQ ID NO: 172. In some embodiments, the TCR alpha chain comprises a CDR3, wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 172. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 84. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 84. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth inWSGR Docket No. 50401-806.601SEQ ID NO: 85. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 85. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 173. In some embodiments, the TCR alpha chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 173.

[0151] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 180. In some embodiments, the CDR3 has an amino acid sequence of SEQ ID NO: 180. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 181. In some embodiments, the TCR beta chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 181. In some embodiments, a TCR alpha chain comprises a CDR3 having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence forth in SEQ ID NO: 178. In some embodiments, the TCR alpha chain comprises a CDR3, wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 178. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 176. In some embodiments, theWSGR Docket No. 50401-806.601TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 176. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 177. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 177. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 179. In some embodiments, the TCR alpha chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 179.

[0152] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 184. In some embodiments, the CDR3 has an amino acid sequence of SEQ ID NO: 184. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 72. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 72. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 73. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 73. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 185. In some embodiments, the TCR beta chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 185. In some embodiments, a TCR alpha chain comprises a CDR3 having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence forth in SEQ ID NO: 182. In some embodiments, the TCR alpha chainWSGR Docket No. 50401-806.601 comprises a CDR3, wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 182. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 176. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 176. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 177. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 177. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 183. In some embodiments, the TCR alpha chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 183.

[0153] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 190. In some embodiments, the CDR3 has an amino acid sequence of SEQ ID NO: 190. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence setWSGR Docket No. 50401-806.601 forth in SEQ ID NO: 191. In some embodiments, the TCR beta chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 191. In some embodiments, a TCR alpha chain comprises a CDR3 having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence forth in SEQ ID NO: 188. In some embodiments, the TCR alpha chain comprises a CDR3, wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 188. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 186. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 186. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 187. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 187. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 189. In some embodiments, the TCR alpha chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 189.

[0154] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 196. In some embodiments, the CDR3 has an amino acid sequence of SEQ ID NO: 196. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 194. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 194. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to anWSGR Docket No. 50401-806.601 amino acid sequence set forth in SEQ ID NO: 195. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 195. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 197. In some embodiments, the TCR beta chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 197. In some embodiments, a TCR alpha chain comprises a CDR3 having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence forth in SEQ ID NO: 192. In some embodiments, the TCR alpha chain comprises a CDR3, wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 192. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 17. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 17. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 18. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 18. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 193. In some embodiments, the TCR alpha chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 193.

[0155] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 164. In some embodiments, the CDR3 has an amino acid sequence of SEQ ID NO: 164. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 72. InWSGR Docket No. 50401-806.601 some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 72. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 73. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 73. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 165. In some embodiments, the TCR beta chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 165. In some embodiments, a TCR alpha chain comprises a CDR3 having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence forth in SEQ ID NO: 162. In some embodiments, the TCR alpha chain comprises a CDR3, wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 162. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 160. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 160. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 161. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 161. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 163. In some embodiments, the TCR alpha chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 163.

[0156] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to anWSGR Docket No. 50401-806.601 amino acid sequence set forth in SEQ ID NO: 202. In some embodiments, the CDR3 has an amino acid sequence of SEQ ID NO: 202. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 203. In some embodiments, the TCR beta chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 203. In some embodiments, a TCR alpha chain comprises a CDR3 having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence forth in SEQ ID NO: 200. In some embodiments, the TCR alpha chain comprises a CDR3, wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 200. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 198. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 198. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 199. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 199. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ IDWSGR Docket No. 50401-806.601NO: 201. In some embodiments, the TCR alpha chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 201.

[0157] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 206. In some embodiments, the CDR3 has an amino acid sequence of SEQ ID NO: 206. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 107. In some embodiments, the TCR beta chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 107. In some embodiments, a TCR alpha chain comprises a CDR3 having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence forth in SEQ ID NO: 104. In some embodiments, the TCR alpha chain comprises a CDR3, wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 104. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 84. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 84. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth inWSGR Docket No. 50401-806.601SEQ ID NO:. 85 In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 85. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 205. In some embodiments, the TCR alpha chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 205.

[0158] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 36. In some embodiments, the CDR3 has an amino acid sequence of SEQ ID NO: 36. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 37. In some embodiments, the TCR beta chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 37. In some embodiments, a TCR alpha chain comprises a CDR3 having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence forth in SEQ ID NO: 208. In some embodiments, the TCR alpha chain comprises a CDR3, wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 208. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 9. In some embodiments, the TCR alpha chain furtherWSGR Docket No. 50401-806.601 comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 9. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 10. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 10. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 209. In some embodiments, the TCR alpha chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 209.

[0159] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 216. In some embodiments, the CDR3 has an amino acid sequence of SEQ ID NO: 216. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 214. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 214. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 215. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 215. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 217. In some embodiments, the TCR beta chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 217. In some embodiments, a TCR alpha chain comprises a CDR3 having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence forth in SEQ ID NO: 212. In some embodiments, the TCR alpha chainWSGR Docket No. 50401-806.601 comprises a CDR3, wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 212. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 210. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 210. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 211. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 211. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 213. In some embodiments, the TCR alpha chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 213.

[0160] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 222. In some embodiments, the CDR3 has an amino acid sequence of SEQ ID NO: 222. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence setWSGR Docket No. 50401-806.601 forth in SEQ ID NO: 223. In some embodiments, the TCR beta chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 223. In some embodiments, a TCR alpha chain comprises a CDR3 having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence forth in SEQ ID NO: 220. In some embodiments, the TCR alpha chain comprises a CDR3, wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 220. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 218. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 218. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 219. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 219. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 221. In some embodiments, the TCR alpha chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 221.

[0161] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 226. In some embodiments, the CDR3 has an amino acid sequence of SEQ ID NO: 226. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 72. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 72. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to anWSGR Docket No. 50401-806.601 amino acid sequence set forth in SEQ ID NO: 73. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 73. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 227. In some embodiments, the TCR beta chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 227. In some embodiments, a TCR alpha chain comprises a CDR3 having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence forth in SEQ ID NO: 186. In some embodiments, the TCR alpha chain comprises a CDR3, wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 186. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 187. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 187. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 224. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 224. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 225. In some embodiments, the TCR alpha chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 225.

[0162] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 230. In some embodiments, the CDR3 has an amino acid sequence of SEQ ID NO: 230. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 5. InWSGR Docket No. 50401-806.601 some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 5. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 6. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 6. In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 231. In some embodiments, the TCR beta chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 231. In some embodiments, a TCR alpha chain comprises a CDR3 having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence forth in SEQ ID NO: 228. In some embodiments, the TCR alpha chain comprises a CDR3, wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 228. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 17. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 17. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 18. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 18. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 229. In some embodiments, the TCR alpha chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 229.

[0163] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to anWSGR Docket No. 50401-806.601 amino acid sequence set forth in SEQ ID NO: 234. In some embodiments, the CDR3 has an amino acid sequence of SEQ ID NO: 234. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 5. In some embodiments, the TCR beta chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 5. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 6. In some embodiments, the TCR beta chain further comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 6 . In some embodiments, the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 235. In some embodiments, the TCR beta chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 235. In some embodiments, a TCR alpha chain comprises a CDR3 having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence forth in SEQ ID NO: 232. In some embodiments, the TCR alpha chain comprises a CDR3, wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 232. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 218. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 218. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 219. In some embodiments, the TCR alpha chain further comprises a complementarity determining region 1 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 219. In some embodiments, the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence set forth in SEQ IDWSGR Docket No. 50401-806.601NO: 233. In some embodiments, the TCR alpha chain comprises a variable region having an amino acid sequence set forth in SEQ ID NO: 233.

[0164] In some embodiments, the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to an amino acid sequence set forth in SEQ ID NO: 238. In some embodiments, the CDR3 has an amino acid sequence of SEQ ID NO: 238. In some embodiments, the TCR beta chain further comprises a complementarity determining ...

Claims

WSGR Docket No. 50401-806.601CLAIMSWhat is claimed is:

1. A recombinant nucleic acid encoding a T cell receptor (TCR) comprising a TCR beta chain and a TCR alpha chain, wherein the TCR binds to an E7 epitope from human papillomavirus (HPV) in complex with a human MHC encoded by an HLA-A*02:01 allele with an EC50 of more than 0.2 nM, and wherein the E7 epitope comprises a sequence of SEQ ID NO: 286.

2. The recombinant nucleic acid of claim 1, wherein the EC50 is more than 0.2 nM and less than 100 nM.

3. The recombinant nucleic acid of claim 1 or 2, wherein the EC50 is more than 0.2 nM and less than 50 nM.

4. The recombinant nucleic acid of any one of claims 1-3, wherein the EC50 is more than 0.5 nM and less than 15 nM.

5. The recombinant nucleic acid of any one of claims 1-4, wherein the TCR does not lead to resistance by a subject being administered with a therapeutic agent comprising the TCR.

6. The recombinant nucleic acid of any one of claims 1-5, wherein the TCR is a soluble TCR.

7. The recombinant nucleic acid of any one of claims 1-6, wherein the TCR does not comprise a TCR alpha constant domain and / or a TCR beta constant domain.

8. The recombinant nucleic acid of any one of claims 1-5 or 7, wherein the TCR is a membrane-bound TCR.

9. The recombinant nucleic acid of any one of claims 1-6, or 8, wherein the TCR further comprises a TCR alpha constant domain and / or a TCR beta constant domain.

10. The recombinant nucleic acid of any one of claims 1-6, or 8-9, wherein the TCR alpha constant domain comprises a sequence of SEQ ID NOs: 287 or 288.

11. The recombinant nucleic acid of any one of claims 1-6, or 8-10, wherein the TCR beta constant domain comprises a sequence of SEQ ID NOs: 289-292.

12. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 170.

13. The recombinant nucleic acid of claim 12, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 5.WSGR Docket No. 50401-806.60114. The recombinant nucleic acid of claim 12 or 13, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 6.

15. The recombinant nucleic acid of any one of claims 12-14, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 171.

16. The recombinant nucleic acid of any one of claims 12-15, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 166; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 167; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 168.

17. The recombinant nucleic acid of any one of claims 12-16, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 169.

18. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 278.

19. The recombinant nucleic acid of claim 18, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 5.

20. The recombinant nucleic acid of claim 18 or 19, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 6.

21. The recombinant nucleic acid of any one of claims 18-20, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 279.

22. The recombinant nucleic acid of any one of claims 18-21, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 17;the CDR2 has an amino acid sequence set forth in SEQ ID NO: 18; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 276.

23. The recombinant nucleic acid of any one of claims 18-22, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%,WSGR Docket No. 50401-806.601 at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 277.

24. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 7.

25. The recombinant nucleic acid of claim 24, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 5.

26. The recombinant nucleic acid of claim 24 or 25, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 6.

27. The recombinant nucleic acid of any one of claims 24-26, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 8.

28. The recombinant nucleic acid of any one of claims 24-27, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 1;the CDR2 has an amino acid sequence set forth in SEQ ID NO: 2; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 3.

29. The recombinant nucleic acid of any one of claims 24-28, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 4.

30. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 15.

31. The recombinant nucleic acid of claim 30, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13.

32. The recombinant nucleic acid of claim 30 or 31, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14.

33. The recombinant nucleic acid of any one of claims 30-32, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%,WSGR Docket No. 50401-806.601 at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 16.

34. The recombinant nucleic acid of any one of claims 30-33, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 9;the CDR2 has an amino acid sequence set forth in SEQ ID NO: 10; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 11.

35. The recombinant nucleic acid of any one of claims 30-34, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 12.

36. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 15.

37. The recombinant nucleic acid of claim 36, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13.

38. The recombinant nucleic acid of claim 36 or 37, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14.

39. The recombinant nucleic acid of any one of claims 36-38, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 16.

40. The recombinant nucleic acid of any one of claims 36-39, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 17 ;the CDR2 has an amino acid sequence set forth in SEQ ID NO: 18; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 19.

41. The recombinant nucleic acid of any one of claims 36-40, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 20.

42. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 28.WSGR Docket No. 50401-806.60143. The recombinant nucleic acid of claim 42, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 26.

44. The recombinant nucleic acid of claim 42 or 43, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 27.

45. The recombinant nucleic acid of any one of claims 42-44, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 29.

46. The recombinant nucleic acid of any one of claims 42-45, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 21; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 22; and he CDR3 has an amino acid sequence set forth in SEQ ID NO: 24.

47. The recombinant nucleic acid of any one of claims 42-46, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 25.

48. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 32.

49. The recombinant nucleic acid of claim 48, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13.

50. The recombinant nucleic acid of claim 48 or 49, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14.

51. The recombinant nucleic acid of any one of claims 48-50, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 33.

52. The recombinant nucleic acid of any one of claims 48-51, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 9; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 10; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 30.WSGR Docket No. 50401-806.60153. The recombinant nucleic acid of any one of claims 48-52, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 31.

54. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 32.

55. The recombinant nucleic acid of claim 54, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13.

56. The recombinant nucleic acid of claim 54 or 55, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14.

57. The recombinant nucleic acid of any one of claims 54-56, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 33.

58. The recombinant nucleic acid of any one of claims 54-57, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 9;the CDR2 has an amino acid sequence set forth in SEQ ID NO: 10; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 34.

59. The recombinant nucleic acid of any one of claims 54-58, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 35.

60. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 36.

61. The recombinant nucleic acid of claim 60, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13.

62. The recombinant nucleic acid of claim 60 or 61, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14.WSGR Docket No. 50401-806.60163. The recombinant nucleic acid of any one of claims 60-62, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 37.

64. The recombinant nucleic acid of any one of claims 60-63, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 9;the CDR2 has an amino acid sequence set forth in SEQ ID NO: 10; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 34.

65. The recombinant nucleic acid of any one of claims 60-64, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 35.

66. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 44.

67. The recombinant nucleic acid of claim 66, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 42.

68. The recombinant nucleic acid of claim 66 or 67, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 43.

69. The recombinant nucleic acid of any one of claims 66-68, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 45.

70. The recombinant nucleic acid of any one of claims 66-69, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 38;the CDR2 has an amino acid sequence set forth in SEQ ID NO: 39; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 40.

71. The recombinant nucleic acid of any one of claims 66-70, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 41.WSGR Docket No. 50401-806.60172. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 50.

73. The recombinant nucleic acid of claim 72, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13.

74. The recombinant nucleic acid of claim 72 or 73, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14.

75. The recombinant nucleic acid of any one of claims 72-74, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 51.

76. The recombinant nucleic acid of any one of claims 72-75, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 46; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 47; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 48.

77. The recombinant nucleic acid of any one of claims 72-76, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 49.

78. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 56.

79. The recombinant nucleic acid of claim 78, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13.

80. The recombinant nucleic acid of claim 78 or 79, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14.

81. The recombinant nucleic acid of any one of claims 78-80, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 57.WSGR Docket No. 50401-806.60182. The recombinant nucleic acid of any one of claims 78-81, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 52; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 53; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 54.

83. The recombinant nucleic acid of any one of claims 78-82, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 55.

84. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 58.

85. The recombinant nucleic acid of claim 84, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13.

86. The recombinant nucleic acid of claim 84 or 85, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14.

87. The recombinant nucleic acid of any one of claims 84-86, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 59.

88. The recombinant nucleic acid of any one of claims 84-87, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 52; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 53; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 54.

89. The recombinant nucleic acid of any one of claims 84-88, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 55.

90. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 58.WSGR Docket No. 50401-806.60191. The recombinant nucleic acid of claim 90, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13.

92. The recombinant nucleic acid of claim 90 or 91, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14.

93. The recombinant nucleic acid of any one of claims 90-92, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 59.

94. The recombinant nucleic acid of any one of claims 90-93, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 9; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 10; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 60.

95. The recombinant nucleic acid of any one of claims 90-94, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 61.

96. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 66.

97. The recombinant nucleic acid of claim 96, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13.

98. The recombinant nucleic acid of claim 96 or 97, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14.

99. The recombinant nucleic acid of any one of claims 96-98, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 67.

100. The recombinant nucleic acid of any one of claims 96-99, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 62;WSGR Docket No. 50401-806.601 the CDR2 has an amino acid sequence set forth in SEQ ID NO: 63; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 64.

101. The recombinant nucleic acid of any one of claims 96-100, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 65.

102. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 74.

103. The recombinant nucleic acid of claim 102, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 72.

104. The recombinant nucleic acid of claim 102 or 103, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 73.

105. The recombinant nucleic acid of any one of claims 102-104, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 75.

106. The recombinant nucleic acid of any one of claims 102-105, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 68; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 69; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 70.

107. The recombinant nucleic acid of any one of claims 102-106, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 71.

108. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 82.

109. The recombinant nucleic acid of claim 108, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 80.WSGR Docket No. 50401-806.601110. The recombinant nucleic acid of claim 108 or 109, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 81.

111. The recombinant nucleic acid of any one of claims 108-110, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 83.

112. The recombinant nucleic acid of any one of claims 108-111, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 76; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 77; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 78.

113. The recombinant nucleic acid of any one of claims 108-112, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 79.

114. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 88.

115. The recombinant nucleic acid of claim 114, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13.

116. The recombinant nucleic acid of claim 114 or 115, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14.

117. The recombinant nucleic acid of any one of claims 114-116, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 89.

118. The recombinant nucleic acid of any one of claims 114-117, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 84; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 85; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 86.WSGR Docket No. 50401-806.601119. The recombinant nucleic acid of any one of claims 114-118, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 87.

120. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 94.

121. The recombinant nucleic acid of claim 120, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 92.

122. The recombinant nucleic acid of claim 120 or 121, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 93.

123. The recombinant nucleic acid of any one of claims 120-122, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 95.

124. The recombinant nucleic acid of any one of claims 120-123, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 52; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 53; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 90.

125. The recombinant nucleic acid of any one of claims 120-124, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 91.

126. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 98.

127. The recombinant nucleic acid of claim 126, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 26.

128. The recombinant nucleic acid of claim 126 or 127, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 27.WSGR Docket No. 50401-806.601129. The recombinant nucleic acid of any one of claims 126-128, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 99.

130. The recombinant nucleic acid of any one of claims 126-129, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 17; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 18; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 96.

131. The recombinant nucleic acid of any one of claims 126-130, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 97.

132. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 106.

133. The recombinant nucleic acid of claim 132, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 104.

134. The recombinant nucleic acid of claim 132 or 133, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 105.

135. The recombinant nucleic acid of any one of claims 132-134, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 107.

136. The recombinant nucleic acid of any one of claims 132-135, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 100; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 101; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 102.

137. The recombinant nucleic acid of any one of claims 132-136, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 103.WSGR Docket No. 50401-806.601138. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 112.

139. The recombinant nucleic acid of claim 138, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13.

140. The recombinant nucleic acid of claim 138 or 139, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14.

141. The recombinant nucleic acid of any one of claims 138-140, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 113.

142. The recombinant nucleic acid of any one of claims 138-141, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 108; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 109; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 110.

143. The recombinant nucleic acid of any one of claims 138-142, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 111.

144. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 118.

145. The recombinant nucleic acid of claim 144, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 5.

146. The recombinant nucleic acid of claim 144 or 145, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 6.

147. The recombinant nucleic acid of any one of claims 144-146, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 119.WSGR Docket No. 50401-806.601148. The recombinant nucleic acid of any one of claims 144-147, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 114; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 115; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 116.

149. The recombinant nucleic acid of any one of claims 144-148, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 117.

150. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 124.

151. The recombinant nucleic acid of claim 150, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 26.

152. The recombinant nucleic acid of claim 150 or 151, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 27.

153. The recombinant nucleic acid of any one of claims 150-152, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 125.

154. The recombinant nucleic acid of any one of claims 150-153, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 120; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 121; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 122.

155. The recombinant nucleic acid of any one of claims 150-154, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 123.

156. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 130.WSGR Docket No. 50401-806.601157. The recombinant nucleic acid of claim 156, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 14.

158. The recombinant nucleic acid of claim 156 or 157, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 130.

159. The recombinant nucleic acid of any one of claims 156-158, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 131.

160. The recombinant nucleic acid of any one of claims 156-159, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 126; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 127; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 128.

161. The recombinant nucleic acid of any one of claims 156-160, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 129.

162. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 134.

163. The recombinant nucleic acid of claim 162, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13.

164. The recombinant nucleic acid of claim 162 or 163, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14.

165. The recombinant nucleic acid of any one of claims 162-164, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 135.

166. The recombinant nucleic acid of any one of claims 162-165, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 84;WSGR Docket No. 50401-806.601 the CDR2 has an amino acid sequence set forth in SEQ ID NO: 85; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 132.

167. The recombinant nucleic acid of any one of claims 162-166, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 133.

168. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 138.

169. The recombinant nucleic acid of claim 168, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13.

170. The recombinant nucleic acid of claim 168 or 169, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14.

171. The recombinant nucleic acid of any one of claims 168-170, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 139.

172. The recombinant nucleic acid of any one of claims 168-171, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 52; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 53; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 136.

173. The recombinant nucleic acid of any one of claims 168-172, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 137.

174. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 142.

175. The recombinant nucleic acid of claim 174, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13.WSGR Docket No. 50401-806.601176. The recombinant nucleic acid of claim 174 or 175, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14.

177. The recombinant nucleic acid of any one of claims 174-176, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 143.

178. The recombinant nucleic acid of any one of claims 174-177, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 9; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 10; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 140.

179. The recombinant nucleic acid of any one of claims 174-178, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 141.

180. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 146.

181. The recombinant nucleic acid of claim 180, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 26.

182. The recombinant nucleic acid of claim 180 or 181, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 27.

183. The recombinant nucleic acid of any one of claims 180-182, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 147.

184. The recombinant nucleic acid of any one of claims 180-183, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 17; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 18; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 144.WSGR Docket No. 50401-806.601185. The recombinant nucleic acid of any one of claims 180-184, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 145.

186. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 150.

187. The recombinant nucleic acid of claim 186, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13.

188. The recombinant nucleic acid of claim 186 or 187, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14.

189. The recombinant nucleic acid of any one of claims 186-188, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 151.

190. The recombinant nucleic acid of any one of claims 186-189, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 52; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 53; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 148.

191. The recombinant nucleic acid of any one of claims 186-190, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 149.

192. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 154.

193. The recombinant nucleic acid of claim 192, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13.

194. The recombinant nucleic acid of claim 192 or 193, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14.WSGR Docket No. 50401-806.601195. The recombinant nucleic acid of any one of claims 192-194, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 144.

196. The recombinant nucleic acid of any one of claims 192-195, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 52; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 53; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 152.

197. The recombinant nucleic acid of any one of claims 192-196, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 153.

198. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 158.

199. The recombinant nucleic acid of claim 198, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13.

200. The recombinant nucleic acid of claim 198 or 199, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14.

201. The recombinant nucleic acid of any one of claims 198-200, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 159.

202. The recombinant nucleic acid of any one of claims 198-201, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 9; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 10; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 156.

203. The recombinant nucleic acid of any one of claims 198-202, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 157.WSGR Docket No. 50401-806.601204. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 164.

205. The recombinant nucleic acid of claim 204, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 72.

206. The recombinant nucleic acid of claim 204 or 205, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 73.

207. The recombinant nucleic acid of any one of claims 204-206, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 165.

208. The recombinant nucleic acid of any one of claims 204-207, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 160; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 161; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 162.

209. The recombinant nucleic acid of any one of claims 204-208, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 163.

210. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 174.

211. The recombinant nucleic acid of claim 210, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 5.

212. The recombinant nucleic acid of claim 210 or 211, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 6.

213. The recombinant nucleic acid of any one of claims 210-212, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 175.WSGR Docket No. 50401-806.601214. The recombinant nucleic acid of any one of claims 210-213, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 84; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 85; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 172.

215. The recombinant nucleic acid of any one of claims 210-214, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 173.

216. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 180.

217. The recombinant nucleic acid of claim 216, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13.

218. The recombinant nucleic acid of claim 216 or 217, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14.

219. The recombinant nucleic acid of any one of claims 216-218, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 181.

220. The recombinant nucleic acid of any one of claims 216-219, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 176; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 177; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 178.

221. The recombinant nucleic acid of any one of claims 216-220, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 179.

222. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 184.WSGR Docket No. 50401-806.601223. The recombinant nucleic acid of claim 222, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 72.

224. The recombinant nucleic acid of claim 222 or 223, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 73.

225. The recombinant nucleic acid of any one of claims 222-224, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 185.

226. The recombinant nucleic acid of any one of claims 222-225, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 176; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 177; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 182.

227. The recombinant nucleic acid of any one of claims 222-226, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 183.

228. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 190.

229. The recombinant nucleic acid of claim 228, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13.

230. The recombinant nucleic acid of claim 228 or 229, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14.

231. The recombinant nucleic acid of any one of claims 228-230, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 191.

232. The recombinant nucleic acid of any one of claims 228-231, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 186;WSGR Docket No. 50401-806.601 the CDR2 has an amino acid sequence set forth in SEQ ID NO: 187; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 188.

233. The recombinant nucleic acid of any one of claims 228-232, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 189.

234. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 196.

235. The recombinant nucleic acid of claim 234, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 194.

236. The recombinant nucleic acid of claim 234 or 235, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 195.

237. The recombinant nucleic acid of any one of claims 234-236, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 197.

238. The recombinant nucleic acid of any one of claims 234-237, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 17; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 18; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 192.

239. The recombinant nucleic acid of any one of claims 234-238, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 193.

240. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 164.

241. The recombinant nucleic acid of claim 240, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 72.WSGR Docket No. 50401-806.601242. The recombinant nucleic acid of claim 240 or 241, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 73.

243. The recombinant nucleic acid of any one of claims 240-242, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 165.

244. The recombinant nucleic acid of any one of claims 240-243, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 160; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 161; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 162.

245. The recombinant nucleic acid of any one of claims 240-244, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 163.

246. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 202.

247. The recombinant nucleic acid of claim 246, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13.

248. The recombinant nucleic acid of claim 246 or 247, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14.

249. The recombinant nucleic acid of any one of claims 246-248, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 203.

250. The recombinant nucleic acid of any one of claims 246-249, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 198; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 199; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 200.WSGR Docket No. 50401-806.601251. The recombinant nucleic acid of any one of claims 246-250, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 201.

252. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 206.

253. The recombinant nucleic acid of claim 252, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13.

254. The recombinant nucleic acid of claim 252 or 253, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14.

255. The recombinant nucleic acid of any one of claims 252-254, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 107.

256. The recombinant nucleic acid of any one of claims 252-255, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 84; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 85; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 204.

257. The recombinant nucleic acid of any one of claims 252-256, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 205.

258. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 36.

259. The recombinant nucleic acid of claim 258, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13.

260. The recombinant nucleic acid of claim 258 or 259, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14.WSGR Docket No. 50401-806.601261. The recombinant nucleic acid of any one of claims 258-260, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 37.

262. The recombinant nucleic acid of any one of claims 258-261, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 9; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 10; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 208.

263. The recombinant nucleic acid of any one of claims 258-262, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 209.

264. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 216.

265. The recombinant nucleic acid of claim 264, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 214.

266. The recombinant nucleic acid of claim 264 or 265, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 215.

267. The recombinant nucleic acid of any one of claims 264-266, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 217.

268. The recombinant nucleic acid of any one of claims 264-267, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 210; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 211; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 212.

269. The recombinant nucleic acid of any one of claims 264-268, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 213.WSGR Docket No. 50401-806.601270. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 222.

271. The recombinant nucleic acid of claim 270, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13.

272. The recombinant nucleic acid of claim 270 or 271, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14.

273. The recombinant nucleic acid of any one of claims 270-272, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 223.

274. The recombinant nucleic acid of any one of claims 270-273, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 218; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 219; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 220.

275. The recombinant nucleic acid of any one of claims 270-274, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 221.

276. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 226.

277. The recombinant nucleic acid of claim 276, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 72.

278. The recombinant nucleic acid of claim 276 or 277, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 73.

279. The recombinant nucleic acid of any one of claims 276-278, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 227.WSGR Docket No. 50401-806.601280. The recombinant nucleic acid of any one of claims 276-279, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 186; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 187; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 224.

281. The recombinant nucleic acid of any one of claims 276-280, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 225.

282. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 230.

283. The recombinant nucleic acid of claim 282, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 5.

284. The recombinant nucleic acid of claim 282 or 283, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 6.

285. The recombinant nucleic acid of any one of claims 282-284, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 231.

286. The recombinant nucleic acid of any one of claims 282-285, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 17; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 18; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 228.

287. The recombinant nucleic acid of any one of claims 282-286, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 229.

288. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 234.WSGR Docket No. 50401-806.601289. The recombinant nucleic acid of claim 288, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 5.

290. The recombinant nucleic acid of claim 288 or 289, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 6.

291. The recombinant nucleic acid of any one of claims 288-290, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 235.

292. The recombinant nucleic acid of any one of claims 288-291, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 218; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 219; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 232.

293. The recombinant nucleic acid of any one of claims 288-292, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 233.

294. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 238.

295. The recombinant nucleic acid of claim 294, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 5.

296. The recombinant nucleic acid of claim 294 or 295, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 6.

297. The recombinant nucleic acid of any one of claims 294-296, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 239.

298. The recombinant nucleic acid of any one of claims 294-297, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 84;WSGR Docket No. 50401-806.601 the CDR2 has an amino acid sequence set forth in SEQ ID NO: 85; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 236.

299. The recombinant nucleic acid of any one of claims 294-298, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 237.

300. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 240.

301. The recombinant nucleic acid of claim 300, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 5.

302. The recombinant nucleic acid of claim 300 or 301, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 6.

303. The recombinant nucleic acid of any one of claims 300-302, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 241.

304. The recombinant nucleic acid of any one of claims 300-303, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 166; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 167; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 168.

305. The recombinant nucleic acid of any one of claims 300-304, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 169.

306. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 244.

307. The recombinant nucleic acid of claim 306, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 26.WSGR Docket No. 50401-806.601308. The recombinant nucleic acid of claim 306 or 307, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 27.

309. The recombinant nucleic acid of any one of claims 306-308, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 245.

310. The recombinant nucleic acid of any one of claims 306-309, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 38; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 39; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 242.

311. The recombinant nucleic acid of any one of claims 306-310, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 243.

312. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 248.

313. The recombinant nucleic acid of claim 312, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13.

314. The recombinant nucleic acid of claim 312 or 313, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14.

315. The recombinant nucleic acid of any one of claims 312-314, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 249.

316. The recombinant nucleic acid of any one of claims 312-315, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 9; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 10; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 246.WSGR Docket No. 50401-806.601317. The recombinant nucleic acid of any one of claims 312-316, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 247.

318. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 252.

319. The recombinant nucleic acid of claim 318, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13.

320. The recombinant nucleic acid of claim 318 or 319, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14.

321. The recombinant nucleic acid of any one of claims 318-320, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 253.

322. The recombinant nucleic acid of any one of claims 318-321, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 176; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 177; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 250.

323. The recombinant nucleic acid of any one of claims 318-322, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 251.

324. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 256.

325. The recombinant nucleic acid of claim 324, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 72.

326. The recombinant nucleic acid of claim 324 or 325, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 73.WSGR Docket No. 50401-806.601327. The recombinant nucleic acid of any one of claims 324-326, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 257.

328. The recombinant nucleic acid of any one of claims 324-327, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 68; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 69; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 254.

329. The recombinant nucleic acid of any one of claims 324-328, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 255.

330. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 262.

331. The recombinant nucleic acid of claim 330, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 26.

332. The recombinant nucleic acid of claim 330 or 331, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 27.

333. The recombinant nucleic acid of any one of claims 330-332, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 263.

334. The recombinant nucleic acid of any one of claims 330-333, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 258; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 259; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 260.

335. The recombinant nucleic acid of any one of claims 330-334, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 261.WSGR Docket No. 50401-806.601336. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 266.

337. The recombinant nucleic acid of claim 336, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 13.

338. The recombinant nucleic acid of claim 336 or 337, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 14.

339. The recombinant nucleic acid of any one of claims 336-338, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 267.

340. The recombinant nucleic acid of any one of claims 336-339, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 52; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 53; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 264.

341. The recombinant nucleic acid of any one of claims 336-340, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 265.

342. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 274.

343. The recombinant nucleic acid of claim 342, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 272.

344. The recombinant nucleic acid of claim 342 or 343, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 273.

345. The recombinant nucleic acid of any one of claims 342-344, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 275.WSGR Docket No. 50401-806.601346. The recombinant nucleic acid of any one of claims 342-345, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 268; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 269; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 270.

347. The recombinant nucleic acid of any one of claims 342-346, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 271.

348. The recombinant nucleic acid of any one of claims 1-11, wherein the TCR beta chain comprises a complementarity determining region 3 (CDR3), wherein the CDR3 has an amino acid sequence set forth in SEQ ID NO: 284.

349. The recombinant nucleic acid of claim 348, wherein the TCR beta chain comprises a complementarity determining region 1 (CDR1), wherein the CDR1 has an amino acid sequence set forth in SEQ ID NO: 282.

350. The recombinant nucleic acid of claim 348 or 349, wherein the TCR beta chain comprises a complementarity determining region 2 (CDR2), wherein the CDR2 has an amino acid sequence set forth in SEQ ID NO: 283.

351. The recombinant nucleic acid of any one of claims 348-350, wherein the TCR beta chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 285.

352. The recombinant nucleic acid of any one of claims 348-351, wherein the TCR alpha chain having a CDR1, CDR2, and a CDR3, wherein, the CDR1 has an amino acid sequence set forth in SEQ ID NO: 46; the CDR2 has an amino acid sequence set forth in SEQ ID NO: 47; and the CDR3 has an amino acid sequence set forth in SEQ ID NO: 280.

353. The recombinant nucleic acid of any one of claims 348-352, wherein the TCR alpha chain comprises a variable region having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to an amino acid sequence set forth in SEQ ID NO: 281.

354. A T cell comprising the recombinant nucleic acid of any one of claims 1-353.

355. The T cell of claim 354, wherein T cell is a CD4+ T cell or a CD8+ T cell.

356. A soluble TCR encoded by the recombinant nucleic acid of any one of claims 1-7 or 9- 353.WSGR Docket No. 50401-806.601357. A pharmaceutical composition comprising: (a) the recombinant nucleic acid of any one of claims 1-353, the cell of claim 354 or 355, or the soluble TCR of claim 356; and (b) a pharmaceutically acceptable excipient or diluent.

358. Use of the pharmaceutical composition of claim 357, for treating an HPV associated cancer.

359. Use of the recombinant nucleic acid of any one of claims 1-353, the T cell of claim 354 or 355, the soluble TCR of claim 356, or the pharmaceutical composition of claim 357 in the manufacture of a medicament for the treatment of cancer.

360. A method of treating an HPV associated cancer in a subject in need thereof, comprising administering to the subject the pharmaceutical composition of claim 357.

361. The method of claim 360, wherein the HPV associated cancer is caused by HPV-16.

362. The method of claim 360, wherein the HPV associated cancer is selected from the group consisting of head and neck squamous cell carcinoma, oropharyngeal cancer, cervical carcinoma, anogenital carcinoma, and penile carcinoma.

363. The method of claim 360, wherein the HPV associated cancer is refractory or relapsed.

Images